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Motivation & outline
Cancer is one of the leading causes of death world wide. According to the World
Health Organization (WHO) 7:6 million deaths, which is about 13% of all deaths,
were the result of cancer in 20081. This frightening number is projected to continue
to rise to over 30 million in 2030. In response the WHO launched its Noncom-
municable Diseases Action Plan that focusses on preventing and controlling cancer.
Prevention of diseases is of course better than treatment or control. However, cancer
treatment is one of the major challenges for present health systems. Eciency and
eect of present cancer treatments are mainly linked to an early detection and pre-
cise diagnosis. Early detection always involves the patients awareness of early signs
and symptoms. A precise diagnosis of cancer is only possible based on tissue biop-
sies, which are judged by a pathologist according to morphological and molecular
properties.
Another way to investigate molecular characteristics of tumor biopsies, which has
been subject to intensive research in recent years, is gene expression proling. In
fact, it has been shown by Hummel et al. (2006) that microarray gene expression
analysis is able to improve the molecular stratication and classify former unknown
cases of lymphoma. We believe that information about expression states of thou-
sands of genes measured simultaneously holds even greater potential. This potential
can be unlocked if gene expression data is combined with additional data from other
experiments that measure specic perturbations on the transcriptome. Such per-
turbations might be stimulation of cell lines with certain compounds, knock-out or
knock-in of specic genes or binding anities of transcription factors to the DNA.
The integration of tumor biopsies with additional experimental data allows the de-
tection of gene clusters within the expression proles that respond to perturbations.
In this thesis the prospects of data integration in this context are subject of chapters
3 and 4. In chapter 3 we will review the data integration literature with respect to
gene expression analysis. This is followed by a detailed description of a novel data
integration method developed during this thesis in chapter 4.
Recently the analysis of single cells has moved into the focus of cancer research.
The present model of disseminated tumor cell (DTC) and early metastatic spread
suggests that single tumor cells disseminate from the primary tumor in a very early
1GLOBOCAN 2008, International Agency for Research on Cancer
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stage of disease and may cause metastasis, even if the primary tumor is removed
early as reported by Hüsemann et al. (2008). According to Scher and Pantel (2009)
the input of DTCs into cancer research is manifold. For example, the analysis of
DTCs could establish new prognostic biomarkers that predict disease recurrence
after surgery or identify patients in need of antiproliferative therapy. However,
the analysis of single cells raises new technological and analytical challenges as the
amount of available sample material is low. Usually clinical samples consist of thou-
sands of cells. In this thesis we investigate single cell microarray gene expression
proling in chapter 5. We compare the performance of several normalization pro-
cedures with respect to dierent applications of gene expression analysis, namely
dierential gene expression analysis and classication. An application of single cell
microarray analysis is given in chapter 6. There we leave the eld of cancer research
and enter reproductive medicine and embryonic research. We analyze samples that
naturally consist of only one cell, the murine zygote. We investigate the very rst
steps of embryogenesis by comparing the single cells of 2  and 3 cell blastomeres.
The aim of this analysis is to answer the question whether there exist conserved dif-
ferences within the transcriptomes of couplets or triplets derived from 2  or 3 cell
blastomeres.
In the introductory part of this thesis, namely chapter 1 and 2, the biological
terms and concepts used throughout this thesis are described. This is followed by
an introduction into the machine learning techniques used in data analysis, namely
classication, clustering and kernel density estimation.
The thesis closes with a summary and nal conclusions.
xvi
Part I
Introduction
1

3We start by introducing the terminological basics and background for the content of
this thesis.
In chapter 1 the most important molecular biological terms used are described. This
is followed by a description of molecular biological techniques and methods that were
used to generate the data sets analyzed in this work. Several textbooks were used for
this part of the introduction namely: Basiswissen Biochemie: mit Pathobiochemie
(Löer, 2009), Biochemie (Stryer, 1996), Lehrbuch der Molekularen Zellbiolo-
gie (Alberts et al., 2005) and Bioinformatics - Sequence and Genome Analysis
(Mount, 2004) .
In chapter 2 a brief introduction into the concepts of machine learning methodology
used is given. This comprises classication, kernel density estimation and clustering.
In this chapter the textbooks The Elements of Statistical Learning (Hastie et al.,
2001), Elements of Computational Statistics (Gentle, 2002) and Semi-Supervised
Learning (Chapelle et al., 2006) as well as the original publications of Kaufman
and Rousseeuw (1990), Rousseeuw (1987) and Tibshirani et al. (2002) were used.
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Chapter 1
Biological Content
1.1 Molecular Biology
Gene Regulation Each eukaryotic cell contains the whole genome of its specic
organism and has therefore the potential to express all genes. However, only a frac-
tion of genes is expressed within a cell in a certain condition and time point. Between
dierent tissues the set of expressed genes diers. This is called dierential gene ex-
pression. It is of crucial importance for all cells to regulate their gene expression
in response to variable environmental conditions. In eukaryotic cells the regulatory
mechanisms vary from the inactivation of genes by methylation via mRNA editing
or degradation to transcription factors. Within an organism the cells interact and
gene regulation is controlled and triggered by a complex network of signals.
Transcription Factors Transcription factors are molecules that can bind to spe-
cic DNA sequences. They can either activate or repress the process of transcription
and are part of the gene regulation machinery.
Dierentiation & Proliferation Highly specialized tissues are responsible for
dierent requirements of an organism. The lungs are responsible for the oxygen
absorption, the muscles for movement and the intestine for the absorption of nu-
trients. However, all the cells of an organism develop out of a single fertilized egg.
As an organism develops many cells are needed and the number of cells increases
via cell division. This increase of cell numbers is called proliferation. In chapter
6 we investigate the very rst cell divisions by analyzing single cells from 2- and
3-cell mice blastomeres and zygotes. In contrast, dierentiation is the process that
5
6specialize a cell to a certain biological task.
Cancer Cancer is a group of diseases characterized by uncontrolled cell prolifer-
ation. The disease is based on the accumulation of mutations within a single cell.
These mutations result in a breakdown of the normal regulatory control mechanisms.
Mutations can be caused by errors during DNA replication, contact with harmful
chemicals, exposure to radiation or be inherited. Tumors can be developed in all
types of tissues and are usually named based on their cellular origin. A tumor can
spread to other parts of the body. This process is called metastasis.
Oncogenes & Tumor Suppressor Genes Genes can be directly involved in the
formation of cancer. One distinguishes between oncogenes and tumor suppressor
genes. Oncogenes are mutated genes that contribute to the development of a can-
cer. They often code for signaling proteins that are involved in the regulation of cell
division. In their mutated form they produce a constant stimulus that drives the cell
to proliferate. Tumor suppressor genes work in the opposite direction of oncogenes.
They code for proteins that keep the cell division under control. However, if a tumor
suppressor gene is mutated the control mechanism can not be maintained. This loss
of control over cell division may contribute to the development of a cancer. Iden-
tication of onco- and tumor suppressor genes is the key to understanding cancer.
Their regulation and protein products are interesting targets for drug development
and therapies.
Lymphoma Lymphoma are a type of blood or hematopoietic cancer that can
be developed in many parts of the body, including the lymph nodes, spleen, bone
marrow and blood. They occur when lymphocytes, a type of white blood cells,
proliferate abnormally. The collective term lymphoma contains many subtypes of
this disease. There are two main types of lymphoma, the Hodgkin lymphoma (HL)
and the non-Hodgkin lymphoma (NHL). The NHL are further classied by their cell
of origin. This cell is either a B- or T-lymphocyte, thus the respective lymphoma
is referred to as B-cell or T-cell lymphoma. B-cell lymphomas comprise about 95%
of all lymphomas. In chapter 4 we analyze data from two aggressive forms, the
diuse large B-cell lymphoma (DLBCL) and the Burkitt lymphoma. While the
data set contains samples from both subtypes the analysis focusses on the DLBCL.
We investigate the inuence of the transcription factor BCL6 on the transcriptome,
since BCL6 is a key oncogene in the development of DLBCL.
7Cell Lines Cells can be grown separated from the original tissue under con-
trolled conditions. This technique is called cell culture. Permanently established
cell cultures that can proliferate indenitely are called cell lines.
In cancer research cell lines derived from tumors are widely used as model organ-
isms. They are exposed to newly developed drugs or other compounds to test their
eects. Another application is the investigation of transcriptome changes given a
certain perturbation. This perturbation can be a silenced or activated gene or the
application of a specic compound that will activate or block receptors. Then the
transcriptome of perturbed cells is compared with control cells without the pertur-
bation using gene expression microarrays. Such experiments give new insights into
the regulatory mechanism triggered by the perturbation. In this work data from cell
line experiments is integrated with gene expression proles of lymphoma patients in
chapter 4. Further we used cell lines to generate the expression data employed in
the evaluation of singe cell gene expression analysis in chapter 5.
81.2 Measuring Techniques
Microarray Today exists a large variety of microarrays technologies to measure
dierent kinds of biological data like gene expression, protein abundance, protein
binding or genomic aberrations. Their advantage compared to other methods is, that
they measure not only one gene or protein at a time, but thousands. Therefore,
microarray data are snapshots of an entire proteome or transcriptome within a
sample at a certain time point. In this work we focus mainly on gene expression
microarray data, which was also the rst application of this technology. There are
two primary types of gene expression microarrays: (i) The cDNA microarray which
was invented by the Pat Brown laboratory in 1995 (Schena et al., 1995) and (ii) the
high-density oligonucleotide array invented by Aymetrix in 1996 (Lockhart et al.,
1996).
The basic concept of any gene expression microarray experiment is to extract
mRNA from a tissue and reverse transcribe it into cDNA. As a prerequisite for
measuring, cDNA is amplied in a way that the relative molecular abundances of
dierent mRNAs are preserved. The cDNA is then labeled with a uorescent dye and
used as a target to bind to complementary DNA sequences. The targets are detected
by single-stranded cDNA or oligonucleotide probes that are attached as xed spots
on a support surface like a glass slide. The abundance of a particular mRNA can be
measured indirectly by quantifying the uorescence intensity of the corresponding
probe spot. A quantication of the measured mRNA abundance can be done by
comparing the spot intensities of a sample to the intensities of a control experiment.
This quantication is not absolute but relative to the control. Figure 1.1 illustrates
the generation and application of cDNA and high-density oligonucleotide arrays.
Until today microarray technologies have been developed to be routine high
throughput methods that have been proven to be a valuable tool of modern molec-
ular biology. Their versatility is highly responsible for their success. They can be
employed to detect dierentially expressed genes between samples of dierent bi-
ological origin (Chee et al., 1996), or to identify a set of genes that discriminates
between dierent types of samples for diagnosis or prognosis (van 't Veer et al.,
2002). They can also be used to dene novel subgroups within a certain sample
population (Alizadeh et al., 2000). Other microarray technologies can be used for
polymorphism analysis (Wang et al., 1998), sequencing (Pease et al., 1994) and de-
9Figure 1.1: Comparison of the production and hybridization steps in (A) cDNA and
(B) high density oligonucleotide arrays.
tection of protein DNA interactions (Ren et al., 2000). Data analyzed in this thesis
primarily originates from gene expression microarray experiments. In chapter 4 we
use additional data from ChIP-on-chip experiments.
qPCR (quantitative Polymerase Chain Reaction) Polymerase chain reaction
is a technique for DNA amplication. In theory, PCR can produce an arbitrary
number of copies out of a single DNA segment. It was developed in the 1980s by
the American biochemist Kary Mullis, who was rewarded with the Nobel Price for
10
chemistry in 1993.
The PCR process runs in cycles, which each consist of three steps, namely de-
naturation, primer annealing and elongation. In each cycle the amount of DNA
molecules is doubled. In the denaturation step the two DNA strains are separated
by heating. Then follows the annealing step in which the temperature is lowered to
allow the primer sequences to bind to the single stranded DNA. In the elongation
step the DNA polymerase replicates the second strain of each single stranded DNA
molecule. It is possible to amplify only specic DNA segments by using only primers
that ank the targeted sequence. Hence PCR allows both, the amplication of the
whole genome or specic DNA segments. PCR can also be used to amplify RNA.
To do so RNA molecules have to be transcribed into cDNA molecules before the
amplication process is started. This transformation is called reverse transcription.
Apart from amplication PCR can also be used to quantify the initial amount
of targeted transcript. This method is called quantitative PCR (qPCR). For the
quantication uorescent dyes are used that are build into the replicated sequence
during the elongation step. With each cycle the dye intensity increases as the num-
ber of transcript copies increase. The number of cycles is counted until a specic
intensity threshold is reached. This number is compared to a reference PCR using
a target sequence with known abundance (Wang et al., 1989). This technique can
be used to detect chromosomal aberrations like copy number changes or to measure
gene expression if qPCR was done on reverse transcribed cDNA.
Apart from being an integral part of experimental protocols generating microarray
data, PCR was used to validate results from microarray gene expression analysis in
chapter 4.
ChIP-on-chip ChIP-on-chip combines chromatin immunoprecipitation (ChIP)
with the microarray technology (chip). The ChIP technique isolates and identies
DNA sequences that were be bound by specic DNA binding proteins, for example
transcription factors (Ren et al., 2000). In principal, DNA is cross linked with the
protein of interest and sheared. Then the DNA fragments with a bound protein
are separated from all other DNA fragments using antibodies specic to the protein
of interest. Depending on the specic method these antibodies are attached to a
solid surface or have a magnetic bead that allows the xation of the protein-DNA
complexes, such that the other DNA fragments can be washed away. The bound
DNA segments are then separated from the protein of interest and puried. After
11
amplication the DNA segments are denatured into single stranded DNA fragments.
These are labeled with a uorescent dye. The labeled fragments are then hybridized
to a DNA microarray. As each spot of the microarray represents a specic location
in the genome one can identify the DNA binding positions by identifying spots
with high uorescence intensities. In chapter 4 we use data from ChIP-on-chip
experiments to identify gene clusters that are targets of the transcription factor
BCL6.
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Chapter 2
Statistical Context
2.1 Machine Learning
Notation This thesis deals with gene expression microarray data. Here we give
the notation that will be used throughout the thesis. We will denote data sets
consisting of n samples and p genes by a matrix X 2 Rpn. Each row xi of X
contains the expression of a single gene across all samples, while each column xj
contains the expression prole of a single sample. Denoting a gene by an index
letter, like any gene g, is equivalent to xg. If we work on more that one data set
simultaneously, we will introduce notional conventions when needed. In some cases
additional information is available that assigns samples into groups or classes. We
will call this information labels and store them in a vector Y with yj 2 [1; : : : ; k]
and j = 1; : : : ; n, where k is the number of classes.
Un-, Semi- & Supervised Learning Machine learning problems are categorized
into three dierent groups, namely un-, semi- and supervised problems. Unsuper-
vised learning seeks to determine how data is structured. Well known examples
of unsupervised methods are clustering and density estimation. Cluster algorithms
aim to separate the data objects into a given number of groups. Density estimation
analyzes how the data objects are distributed in the data space.
In contrast, supervised learning problems arise from data sets that consist of
inputs and outputs. Inputs could be expression proles xj of patient samples and
the corresponding outputs could be class labels yj. Supervised methods aim to
predict the output from the inputs. Applications of supervised learning are for
13
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example classication and regression methods.
Semi-supervised problems are halfway between supervised and unsupervised prob-
lems. Here the output information is given only for a part of the inputs, meaning
that labels are only available for some expression proles. Similar to supervised
methods the goal is to predict the outputs of all inputs. Semi-supervised learning
methods extend supervised approaches by incorporating structural or distribution
properties learned from the unlabeled inputs.
2.1.1 Classication
Classication is one of the major applications of supervised learning. Given a gene
expression data set X with corresponding class labels Y , we denote a classier or
prediction model that has been estimated from training data as fclass(X). For a
certain expression prole xj the predicted label is denoted as fclass(xj). Dierences
between fclass(xj) and the corresponding label yj are called errors. The number of
errors made by a classier is measured by a loss function
L(yj; fclass(xj)) =
8<:1 if yj = fclass(xj)0 if yj 6= fclass(xj) (2.1)
One distinguishes between two types of errors, the training and the test error. The
training error is the average loss over the training samples
err =
1
n
nX
j=1
L(yj; fclass(xj)) : (2.2)
However, to assess the quality of a classier one uses the test error, which is
estimated by the average loss over an independent test data set X 0 containing n0
samples and known class labels Y 0
Err =
1
n0
n0X
j=1
L(y0j; fclass(x
0
j)) : (2.3)
In the next part follows a detailed explanation of the nearest shrunken centroids
(NSC) classication algorithm.
Nearest Shrunken Centroids The NSC method was proposed by Tibshirani
et al. (2002) and is designed for the analysis of microarray expression data. In
this context the task is to classify and predict the diagnostic category of a sample
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based on its gene expression prole. This classication problem is challenging since
one is faced with a large number of genes from which to predict classes for a small
number of samples. It is important to identify the genes that contribute most to
the classication, so that non-contributing genes can be discarded.
Given a gene expression data set X and a vector of corresponding class labels
Y 2 1; 2; : : : ; K, let Ck be a vector of indices of the nk samples belonging to class k.
The centroid xk of a class k is dened as the average expression per gene across all
samples of that class: xik =
P
j2Ck xij=nk. Similar, the overall centroid is dened
as the average expression per gene across all samples xi =
Pn
j=1 xij=n. In order
to identify genes that contribute most to the classication the class centroids are
shrunken stepwise towards the overall centroid. This is done by comparing the
centroid of each class k to the overall centroid. We dene a dierence dik for each
gene as
dik =
xik   xi
mk  (si + s0) (2.4)
where each gene is standardized by the pooled within-class standard deviation
s2i =
1
n K
X
k
X
j2Ck
(xij   xik)2 (2.5)
and mk =
p
1=nk + 1=n, so that mk  si is equal to the estimated standard error of
the numerator in dik. The positive constant s0 guards against large dik values arising
from genes with low overall variance. Shrinkage is done by reducing the values of
dik stepwise towards zero. This process is tuned by a parameter 
d0ik = sign(dik)(jdikj  )+ ; (2.6)
where sign(x) equals 1 or  1 if x is positive or negative and (jdikj   )+ denotes
the maximum of jdikj    and zero. Genes are discarded if d0ik becomes zero. A
shrunken class centroid x0ik can then be dened by rewriting equation 2.4 as
x0ik = xi +mk(si + s0)d
0
ik : (2.7)
A sample xj is classied by determining the closest shrunken class centroid. The
distance between a class centroid and a sample is measured by the discriminant
score
k(xj) =
pX
i=1
(xij   x0ik)2
(si + s0)2
  2 log k (2.8)
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where k is the prior probability of class k, that is dened as the overall frequency
of class k in the population, hence
PK
k=1 k = 1. Usually k is set to nk=n. The
prediction model is then dened as
fclass(xj;) = r where r(xj) = min
k
k(xj) : (2.9)
The result of the NSC classier depends on the chosen shrinkage parameter . We
chose so that the test error is minimized by employing a cross validation procedure
as described below.
Cross Validation Cross validation (CV) is a method widely used for model
assessment and selection. Here we will consider CV in the context of classication.
CV is one of the simplest ways for estimating the test error of a classier or prediction
model. Given a gene expression data set X with corresponding class labels Y and a
prediction model fclass(X) one can assess the performance of the fclass(X) using an
independent test set. Unfortunately, this is often not possible since data is scarce.
To circumvent this problem CV uses one part of the available data to train the
model and another part to test it. The data is split into K subsets (or folds) of
equal size (K-fold CV). Each of the K subsets is predicted by a model trained on
the other K   1 sets. Figure 2.1(a) illustrates the arrangement of a data set into K
subsets and the K training / prediction runs. The test error is then calculated by
combining the errors in the K predicted subsets. The CV estimate of the test error
is dened as
ErrCV =
1
n
nX
j=1
L(yj; f
 k(j)
class (xj)) (2.10)
where f
 k(j)
class (xj) is the prediction model trained without the subset k that contains
sample j. Common choices of K are 5 or 10. If K equals n one speaks of leave-one-
out cross validation. In this work 10-fold CV was used if not stated otherwise.
If the training procedure of a prediction model depends on a tuning parameter ,
one can use CV to determine the optimal choice of . In case of the NSC classier
 is the amount of shrinkage. We index the set of models by fclass(xj;). For each
 the CV error is dened as
ErrCV () =
1
n
nX
j=1
L(yj; f
 k(j)
class (xj;)) : (2.11)
ErrCV is an estimate of the test error as a function of . The optimal choice of
the tuning parameter  is 0 that minimizes this function. The optimal prediction
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(a) (b) (c)
Figure 2.1: (a) Cross validation scheme: Each row represents an individual classi-
cation run, while the columns indicate the division of the samples into k sub sets.
During each run, the classier is learned on the training set and used to predict the
test set. (b) Density estimation for a small data set consisting of 20 elements. The
density estimate at each point (black line) is the average contribution from each of
the Gaussian kernels (red lines). The kernels were scaled down by the factor of 20
to t in the graph. The data points are indicated by vertical bars at the bottom.
(c) Arrangement of elements involved to calculate the silhouette s(i) of element xi
belonging to cluster A. B is the nearest neighborhood cluster of xi and C is an
other, more distant cluster.
model is then fclass(X;
0). In case of the NSC classier 0 is determined by trying
dierent choices of .
2.1.2 Kernel Density Estimation
Given the gene expression data set X we assume that the p genes xi are sampled
independently from an unknown distribution. Kernel density estimation (KDE) is
an unsupervised learning procedure that aims to estimate the probability density
function fdens(x) from the given data set X, for any x 2 Rp. A local estimate of the
probability density at x has the form
f^dens(x) =
#fxi 2 N (x)g
p 
(2.12)
where N (x) is a small metric neighborhood around x of width  and #f: : :g counts
the number of genes in N (x). This function tends to be rough, since genes can either
be inside or outside a neighborhood N (x). A smoother function can be achieved by
using the Parzen estimate, which weights the counting as a function of distance to
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xi
f^dens(x) =
1
p 
pX
l=1
K(xl; x) (2.13)
where K(xl; x) is a function with bandwidth  that gives decreasing weights to
genes xl as the distance to x increases. K can be seen as a function that measures
the similarity between two genes. The closer the genes are, the higher is their
similarity. Such functions are also called kernels. The Gaussian kernel is a popular
choice for K. Assuming mean zero and standard deviation  equation 2.13 has the
form
f^dens(x) =
1
p
p
22
pX
l=1
exp
 jjxl   xjj2
22

: (2.14)
An example for density estimation using a Gaussian kernel is shown in Figure 2.1(b).
The bandwidth  of the kernel is a parameter that has a strong inuence on
the resulting density estimate. Small  lead to under-smoothing resulting in spu-
rious data artifacts. On the other hand large values lead to over-smoothing which
obscures much of the underlying data structure. A popular measure to assess the
accuracy of the estimated density function is the mean integrated squared error
(MISE) suggested by Rosenblatt (1971):
MISE = Ejfdens(x)  f^dens(x; )j2 = 1
p
pX
i=1

fdens(xi)  f^dens(xi; )
2
(2.15)
where f^dens(x; ) is a set of estimated density functions indexed by . However, this
measure assumes that the true density is known which is usually not true. This led to
numerous data driven bandwidth selection methods of which the cross validation and
plug-in methods suggested by Rudemo (1982), Bowman (1984), Park and Marron
(1990) and Sheather and Jones (1991) are most popular and well established for low
dimensional data. Unfortunately, when working with high dimensional data like gene
expression measurements such methods are not applicable as they are computational
complex and time intensive. A careful selection by hand is more practicable.
2.1.3 Clustering
Clustering can be dened as the segmentation of data based on a (dis-) similarity
measure. This segmentation results in a grouping of data objects into subsets or
'clusters', such that data objects in the same cluster are more similar than data
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objects in dierent clusters. Importantly, each object needs to be assigned to exactly
one cluster. Additionally, some cluster methods arrange the clusters in a natural
hierarchy. This is done by successively grouping the clusters themselves so that at
each level of hierarchy clusters within the same group are more similar as those in
dierent groups.
There exist dierent types of cluster algorithms. A very popular type is combi-
natorial clustering. Such algorithms directly assign data objects to clusters without
referring to probabilistic data models. Given a gene expression data set X, the data
objects that are to be clustered can be genes as well as samples. We dene the dis-
similarities between each pair of data objects, here samples, by a distance function
d(xj; xl). The pairwise distances are stored in a symmetric matrix D. A popular
distance measure is the Euclidean distance
Djl = d(xj; xl) =
vuut pX
i=1
(xij   xil)2 : (2.16)
Clustering aims to separate the samples into K clusters Ci, with i = 1; : : : ; K where
each cluster Ci stores the sample indices of cluster i, so that samples within the
same cluster are more similar than samples within dierent clusters. The within
cluster distances, can be measured by a loss function
Dwithin =
KX
k=1
X
j2Ck
X
l2Ck
Djl : (2.17)
A clustering that minimizes Dwithin will be optimal, as it automatically maximizes
the between cluster distances
Dbetween =
KX
k=1
X
j2Ck
X
l =2Ck
Djl (2.18)
since
Dtotal = Dwithin +Dbetween =
nX
j=1
nX
l=1
Djl : (2.19)
The optimal clustering can be found by enumerating all possible partitions into
K clusters. However, this is only feasible for small data sets as the number of
combinations growth rapidly with increasing data size. To circumvent this problem
practical combinatorial cluster algorithms try to examine only a small fraction of all
possible partitions. The goal is to identify a small subset that is likely to contain the
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optimal one, or at least a good suboptimal partition. The algorithm that was used
in the thesis is partitioning around medoids that is described in the next section.
Partitioning around Medoids The partitioning around medoids (PAM) algo-
rithm was proposed by Kaufman and Rousseeuw (1990). Given a gene expression
data set X and the number of clusters K, the method aims to nd a set M of K
representative data objects (medoids). This set denes a clustering by dividing the
data objects into K groups, so that each object belongs to its nearest medoid. The
set of medoids is chosen such that the sum of distances of each data object to its
closest medoid is minimized. The PAM algorithm consists of two phases, the build
phase and the swap phase. During the build phase K medoids are added consecu-
tively to the set of medoids M , while in the swap phase this set is improved. In the
following we assume that we cluster the samples xj of the gene expression data set
X.
The build phase is initialized by selecting the rst medoid m1. This is the sample
that minimizes the sum of dissimilarities between itself and all other samples. Hence,
m1 is the sample that is most centrally located in the data set. All other medoids
mi with i = 2; : : : ; k are chosen iteratively by maximizing the loss function
Lbuild(xj) =
nX
l=1

min
m2M
[d(m;xl)]  d(xj; xl)

(2.20)
where minm2M [d(m;xl)] is the minimal distance between a sample xl and the al-
ready chosen medoids m, and d(xj; xl) is the distance between two samples xj and
xl. Lbuild(xj) is the number, by that the sum of distances between samples and their
closest medoids would be reduced if xj was added to the set of medoids. In each
iteration step Lbuild is calculated for all samples xj and the sample that maximizes
Lbuild is added to the set of medoidsM . This procedure is repeated until K medoids
are found.
In the swap phase the algorithm aims to improve the set of medoids M and
therefore also the clustering implied by M . This is done by iteratively searching the
pair of objects (mi; xj) that if swapped, reduces sum of distances between samples
and their closest medoid most. A swap (mi; xj) means that mi is removed from and
xj is added to the set of medoids. We denote the new set of medoids generated by
a swap as M 0. The loss function Lswap measures the change of minimal distances
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between samples and their nearest medoids induced by the swap (mi; xj).
Lswap(mi; xj) =
nX
l=1
min
m02M 0
d(m0; xl) 
nX
l=1
min
m2M
d(m;xl) (2.21)
Details of an ecient implementation of this loss function can be found in Kaufman
and Rousseeuw (1990). Lswap(mi; xj) can take negative or positive values depending
on whether the swap was benecial or not. Negative values indicate benecial swaps
as sum of minimal distances between samples and their closest medoids is reduced.
The optimal swap is the one that minimizes Lswap. This iteration is repeated until
no benecial swap remains.
Following this heuristic procedure the resulting partition will not necessarily be
the global optimum with minimal sum of the within cluster distances Dwithin (see
equation 2.17) but a good approximation. The number of clusters K in which the
data set is separated is a parameter and has to be specied. To select the optimal
K a measure is needed that assesses the quality of a given clustering. However, sum
of distances between data objects and their closest medoid, which is a result of the
PAM procedure, or Dwithin can not be used, as it decreases naturally with increasing
K. Because of this an external cluster validation score has to be used. In this thesis
the silhouette score is employed.
Silhouettes Various methods are available that segment a given data set into a
set of K clusters, like K means, K medians or the PAM algorithm that is used
throughout this thesis. All of these methods result in a set of clusters, where each
cluster contains a certain number of data objects. However, it remains unclear if
these clusters reect a structure that is truly present in the data, or if the data
was just segmented into some articial groups. In the end, cluster methods always
segment the data intoK groups, regardless whether this is supplied by data structure
or not. A method is needed that assess the quality of a given clustering. Dierent
methods have been proposed in the literature and some of them were compared by
Smolkin and Ghosh (2003). The various methods mainly dier in their denition
of cluster quality. In this thesis we employ the method proposed by Rousseeuw
(1987) and calculate silhouettes to assess cluster quality. Using silhouettes, clusters
are of high quality if data objects within the same cluster have low dissimilarities
or distances compared elements in dierent clusters. This denition is particularly
justied with respect to the PAM algorithm, since PAM aims to segment data, such
that the within cluster distances are minimized.
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Given a gene expression data set X, a matrix of pairwise distances D and a set
of clusters, then the silhouette si of a sample xi belonging to cluster A is dened as
si =
bi   ai
max (ai; bi)
(2.22)
where
ai =
1
NA
X
xj2A
d(xi; xj) (2.23)
is the average distance of xi to all other samples of A, with NA being the number
of samples in A, and
bi = min
C 6=A
1
NC
X
xj2C
d(xi; xj) (2.24)
is the minimal average distance of xi and all samples of any cluster C dierent from
A. We denote the cluster for which the minimum bi is achieved as neighbor B of xi.
Figure 2.1(c) illustrates the arrangement of the clusters A, B and C. If a cluster
contains only one element si = 0.
From the denition above follows that
 1  si  1 (2.25)
for each sample xi. Large si, that are close to 1, imply that the within cluster
dissimilarity ai is much smaller than any between cluster dissimilarity bi. Hence, xi
can be considered as well clustered. Vice versa small values of si mean that ai is
much larger than bi, so that on average xi is situated much closer to its neighbor
cluster B than to A. Therefore it seems to be more natural to assign xi to its
neighbor B, meaning that xi has been misclassied. If si is about zero, then ai and
bi are approximately equal and it is not clear if xi belongs to cluster A or B.
The silhouettes dene a measure how well each sample xi matches the given
clustering. To assess the quality of a given clustering we calculate the average
silhouette
s =
NX
i=1
si : (2.26)
One can compare a set of dierent clusterings by comparing their average silhouettes.
The clustering that obtains the maximal average silhouette ts best to the data
structure. Following this, the parameter K of the PAM algorithm can be tuned by
maximizing the average silhouette.
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2.1.4 Dierential Gene Expression
Given a gene expression data set X consisting of two dierent types of samples, for
example tissue biopsies of healthy (group A) and diseased patients (group B), then
dierentially gene expression analysis describes a set of methods that answer the
question whether the expression levels of a gene xi diers systematically between
the two groups. This dierence is usually dened as the dierence between the mean
expression within group A and B.
While the details may dier depending on the method, the general concept is to
assume that a gene is not dierentially expressed between the groups and then test
this null-hypothesis using an appropriate statistical test. Formally we dene the
null-hypothesis H0 for each gene g:
H0 : The gene is not dierentially expressed.
If H0 is rejected by the test, then g is considered to be dierentially expressed
between the two classes. The test that is most commonly used is Student's t-test,
which combines the mean dierence between the groups with the variance within
the groups. Assuming equal variance in both groups the t-score is dened for each
gene i as:
ti =
xiB   xiA
si
; (2.27)
where xiA =
1
nA
P
j2A xij, the value of xiB is dened similar, and nA and nB are the
number of samples in the groups. The pooled standard deviation si is dened as
s2i =
1=nA + 1=nB
nA + nB   2
X
k=fA;Bg
X
j2k
(xij   xik)2 : (2.28)
A look-up of ti in the t-distribution delivers the probability (p-value) of obtaining a
test statistic with absolute value of at least jtij by chance. The p-value is then used
to decide whether H0 is rejected or not. If the p-value is below a certain signicance
threshold, usually 0.05, H0 is rejected and a gene is said to be dierentially ex-
pressed. However, in the context of gene expression analysis this raw p-value can be
misleading since several thousand genes are tested simultaneously. A large number
of simultaneous tests leads to an unnatural high rejection rate of H0. The percent-
age of genes equal to the selected signicance threshold will be reject H0 by chance.
This observation is called multiple-testing problem. Several statistical methods have
been developed to correct the raw p-values for multiple testing. Throughout this
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thesis the method proposed by Benjamini and Hochberg (1995) was used. The re-
sulting adjusted p-values (Padj) reect the false discovery rate (FDR), which is the
expected proportion of incorrectly rejected null hypotheses.
Part II
Genomic Data Integration
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This part focusses on genomic data integration in the context of gene expression
experiments using microarray technology.
We begin in chapter 3 with reviewing the literature on data integration methods
and concepts. Since data integration is a broad eld with application ranging across
various methods, data sources and types, we will focus on literature that is closely
connected to the topic of this thesis.
We continue in chapter 4 with the introduction of a novel data integration method
for the simultaneous analysis of clinical microarray gene expression proles and ex-
perimental data.
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Chapter 3
A review on genomic data
integration
In recent years, the number of available molecular biological methods has immensely
increased. Today, modern technologies allow an almost complete characterization of
biologic samples on the cellular level. Complementary properties include determi-
nation of genotypes using PCR or DNA sequencing and investigation of the DNA
methylation status as well as transcriptome, proteome and metabolome snapshots.
Further, chromatin immunoprecipitation assay like ChIP-seq allow protein-DNA in-
teraction studies. Additionally, protein-protein interaction and protein localization
screens are available that allow deeper insights into the biomolecular interplay within
cells. Many more methods exist, but not all can be mentioned here. However, even
if partly complementary, each proling method sheds dierent light on the function-
ing and malfunctioning of cells. Their joint full potential can only be realized when
dierent sources are combined. Furthermore, research is done on and with dierent
species and model organisms. New challenges arise in cross-species analyzes since
genomes and biomolecular interplay are similar but not identical. However, the
value of model organism in biological and medical research has been shown in many
applications. The development of new drugs and therapies always involves animal
tests and cell culture experiments. Thus, integrating data from dierent sources
is an important part of modern biomedical research. An important aspect of data
integration is the development of tailored statistical methods that are able to lever-
age knowledge contained within a diverse range of data sources and at the same
time, being able to provide evidence to answer the types of question being posed
29
30
by the research community as a whole. While the concept of statistical data inte-
gration is self evident, its realization in genomics is challenging. Obstacles include
the heterogeneity of experimental setups, study designs, proling platforms, sample
handling, and data management. Furthermore, missing meta-data and insucient
documentation of heuristic and complex multistep analysis procedures complicate
the endeavor.
According to Pavlidis et al. (2002) data integration methods can be divided into
three dierent types depending on the analysis step at which the integration is done.
They distinguish between early, intermediate and late integration. Early integra-
tion takes place on the level of input data by simply unifying dierent data sets
to a single one. The analysis is then done by applying standard methods to the
unied data. This approach demands that the dierent data sets are of similar type
or have a common feature space and scale. For example one can combine dierent
gene expression data sets if the same platform was used, or if the platforms dier
the measured genes overlap. In contrast late integration takes place on the level of
analysis results. Here data from dierent sources is analyzed individually and the
nal statistical results are combined. Following this approach heterogeneity in data
type and analysis procedure can be overcome. Intermediate integration describes the
simultaneous analysis of several data sources. The integration step is implemented
within the analysis procedure. Such methods are more complex than the analysis
of a single source and are often tailored towards a specic problem. However, si-
multaneous analysis allows a more exible manipulation of the integration process.
In their work Pavlidis et al. (2002) shows that the intermediate integration is often
superior to early and late approaches but requires sophisticated weighting of each
data type.
In biomedical research late data integration enjoys great popularity as it allows
the combination of heterogeneous data types. The prerequisite for late data inte-
gration is converting data from dierent sources into a common format. One format
that is widely used are gene sets or ranked lists of genes as they can represent a
variety of dierent informations like expression dierences, binding anities and
molecular functions or processes. Dierent methods have been proposed by Beiss-
barth and Speed (2004), Subramanian et al. (2005) and Lottaz et al. (2006) tailored
towards specic problem settings. In order to gain biological insights from a gene
list it is necessary to analyze the functional annotations of all genes in the list.
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These annotations were experimentally determined and validated. Each annotation
describes properties of a set of genes or their products. Each gene may have several
annotations. Beissbarth and Speed (2004) identify annotations that are statistically
signicant within a given gene list by comparing the annotation present in the list
with a control set of genes. While the gene list of interest is usually a handful of genes
showing strongest response to the experiment, the control set can be a database of
annotated genes or all annotated genes represented on a microarray. Annotations
signicantly over represented in the gene list compared to the control set are de-
scriptive for the list and experiment. A major drawback of this over-representation
analysis is that the gene list was usually produced by a single-gene analysis like
dierential expression analysis. This may miss important eects on pathways, since
cellular processes often aect sets of genes. For instance, a relative small increase in
the expression of all genes encoding members of a metabolic pathway may dramat-
ically inuence the biologic processes regulated by that pathway more dramatically
than a high increase of expression in a single gene. To overcome this problem Sub-
ramanian et al. (2005) suggest to measure the enrichment of gene sets in ranked
lists that include all genes measured in the experiment. Consequently they call
their approach gene set enrichment analysis (GSEA). Given multiple ranked gene
lists Lottaz et al. (2006) detects considerable overlaps among the top-ranking genes.
Gene sets conserved across ranked lists emerging from dierent experiments (dier-
ent species) may hold information about conserved biological processes.
Integration on the level of gene lists avoids the need for joint quantitive data models
that describe the dependencies between individual proles.
A quantitative early integration approach is the concatenation of feature vectors
from dierent platforms in the context of classication problems. If several types
of high dimensional readouts are available for the same group of samples, predic-
tive signatures can be constructed by combining selected features across all data
types thus exploring potential complementary information. Somewhat surprisingly,
several authors observed only marginal improvements in classication accuracy re-
sulting from early data integration. Boulesteix et al. (2008) report on several cancer
types where the integration of microarray data with standard clinical predictors,
like age or sex is not benecial. The authors give two possible explanations for this
observation. First, the microarray data might be simply not relevant for the classi-
cation problem and therefore not improve any classier nor be able to achieve high
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accuracy alone. Second, the microarray is relevant for the prediction problem, but
redundant or weaker than the already available clinical parameters. In this scenario
classication on the microarray data alone would have good performance. However,
such redundancy does not imply a causal relationship between clinical parameters
and gene expression. Edén et al. (2004) already observed that 'good old' clinical
markers have similar prognostic power as microarray gene expression data. Similar
results were reported by Lu et al. (2005) in the context of prediction protein-protein
interactions from genomic features like mRNA co-expression, functional similarity
or phylogenetic proles. The authors extended the original feature list of Jansen
et al. (2003) by additional features. However, even if those new features showed
high univariate prediction strength and were largely conditionally independent no
improvement of classier performance was observed. Lu et al. (2005) reason, that
integrating a few good features already approaches the maximal predictive power,
or limit, of current genomic data integration.
Both examples show that simply piling up more and more data sources will not nec-
essarily lead an improvement of existing analysis results or new biological insights.
In contrast to integrating several data sources within the same sample population
data integration methods can also be used to aggregate information across dierent
sample populations. A prominent example for this application is the integration of
clinical and experimental sample population in the eld of gene expression analysis.
In this context Bild et al. (2006) combined expression data generated experimen-
tally by overexpression of active oncogenes in quiescent primary human mammary
epithelial cells (HMECs) with tumor samples of various carcinomas. Oncogene spe-
cic gene signatures were identied by comparing the oncogene transfected HMECs
with a control group employing a Bayesian binary regression procedure proposed by
West et al. (2001). These signatures were then used to predict oncogenic activation
probabilities of the tumor samples by applying the regression model. The authors
showed that combinations of activation probabilities of dierent oncogenes can pre-
dict outcome and treatment eciency of the cancer samples. This analysis strategy
is sequential in that predictive gene sets are identied and combined to predictive
signatures in the HMECs only. In a second independent integration step they are
applied to clinical data. Note that this procedure is fully supervised as signatures
are not aected by properties of the clinical data.
The exact opposite sequential analysis strategy was described by Läuter et al. (2009).
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The authors start their analysis on the clinical data. For each gene they generate a
gene set by selecting all genes that exceed user a dened correlation threshold with
the respective gene. Those gene sets are then tested for joint dierential expression
between the dierent experimental conditions within the HMECs. The authors re-
ject all gene sets that do exceed a certain threshold of signicance. Although the
authors ensure correlation between genes within the tumor samples and joint dier-
ential expression in the HMECs, the HMECs do not inuence the formation of gene
clusters.
The rst analysis approach combining both data sets from the onset was described
by Bentink et al. (2008). This new approach is based on an unsupervised class
discovery procedure proposed by von Heydebreck et al. (2001) that searches for bi-
partitions within a gene expression data. Bentink et al. (2008) rened this method
to meet a semi-supervised scenario in which the tumor data is the unlabeled and
the HMECs the labeled data. This semi-supervised approach allows the authors
to nd classication of tumor samples based on coherently expressed genes, that
simultaneously separate experimental conditions.
In the owing chapter of this thesis we will complement and extend the approach
of Bentink et al. (2008). We will develop a novel data integration strategy named
guided clustering that combines experimental and clinical high throughput data
of possibly dierent genomic data types. Guided clustering is tailored to analysis
scenarios, where the construction of a diagnostic signature is not driven by class
labels on the clinical data, for instance disease types or clinical outcomes, but by
a biological focus for example the activity of a transcription factor or an entire
pathway. The biological focus of the signature is established by a complementing
experimental study on model organisms like cell lines or mice. Examples for those
experimental studies are cell line perturbation experiments as performed by Bild
et al. (2006) or proling of CpG methylation status as done by Gebhard et al.
(2006). Guided clustering uses a density estimation approach to identify sets of
genes that show strong response to the experimental condition while at the same
time display coherent expression across the clinical data set. In contrast to the
semi-supervised approach of Bentink et al. (2008) guided clustering operates fully
unsupervised. Nevertheless the feature selection procedure that drives ordering of
patient samples is guided by the complementing experimental data. Furthermore
guided clustering extends the framework of previous methods in that it allows the
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integration of data from dierent genomic platforms. Instead of separating clinical
samples into classes our approach provides quantitative predictions of experimental
conditions like pathway activation.
In principal, guided clustering can be applied to any data integration problem that
links a sample clustering problem to a feature selection problem driven by a second
data set. In the next chapter we will introduce our method in detail and compare
its performance with other approaches. Further, we will report on two exemplary
applications: (i) The prediction of transcription factor activity in clinical samples
guided by a chromatin immunoprecipitation experiment and (ii) the prediction of
pathway activity guided by cell culture perturbation experiments.
Chapter 4
Guided Clustering
4.1 Problem Setting
Gene expression analysis of cancer biopsies has been subject of intensive research
in recent years. A detailed characterization of patient samples is vital for diagnosis
and treatment. There exists a multitude of techniques that allow determination of
dierent characteristics, for example staining of protein markers, comparative ge-
nomic hybridization (CGH) to determine genomic aberrations and other microarray
technologies that create snapshots of the transcriptome or proteome. In practice not
every technique can be applied to every sample since modern biomolecular meth-
ods are often cost intensive. However, due to the interaction between all cellular
components and processes malfunctions can be observed with several measurements.
For example genomic aberrations can be directly detected by CGH, but they will
also eect the transcriptome and proteome, so that they can often be detected by
microarrays too as shown by Mullighan et al. (2009). Gene expression microarrays
have been proven to be a valuable tool to distinguish between cancer types and sub-
types (Golub et al. (1999), Alizadeh et al. (1999), Bea et al. (2005) and Dave et al.
(2006)) and also dened new disease subtypes (Alizadeh et al. (2000) and Sotiriou
et al. (2003)). This renement of diagnosis can greatly improve the treatment ef-
ciency of patients, since dierent cancer subtypes show dierent drug resistances
(Staunton et al., 2001). Obviously, it would be extremely helpful, if one could specif-
ically design experiments to search for subgroups of interest. Experiments necessary
to dene such groups are for example knock-down through RNAi, the transfection
of constitutively active forms of genes, or application of drugs. However, such ex-
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periments can not be conducted directly on the patient population. This lead to
the approach to perform experiments of interest on model organisms, observe the
responses and search similar patterns in patient data. For example, gene expression
proles of a model organism can measure the gene-wise response to certain pertur-
bations. The knowledge of those responses have two mayor benets: (i) It may guide
to potentially interesting sets of correlated genes, since they react to perturbation,
and (ii) delivers a possible explanation for the coherent expression among patient
samples. This setting leads to the data integration problem of identifying sets of
genes that are coherently expressed across patient samples and showing perturba-
tion response in a model organism. In the following we will refer to the perturbation
experiment as the guiding data.
Let Tij be a matrix of tumor expression proles and Gij the guiding data, where
rows i denotes genes while columns j denotes samples. For simplicity, we assume that
the same proling platform is used and hence the same genes are monitored in both
data sets. The guiding data set G consists of two types of samples: Those which were
subject to perturbation and the corresponding unperturbed control group. Since
we know which proles were experimentally perturbed and which not the guiding
data set is labeled. The labels are stored in a binary vector Y , where a perturbed
prole is indicated by a one and a control sample by a zero. Like experimental
perturbations, somatic mutations in cancers can eect gene regulation and leave
similar traces in expression proles. Hence, we assume that the eect modeled by
the perturbation experiment is also present within the tumors samples and varies
across T due to dierent somatic mutations. However, a priori it is unknown in
which tumor samples a perturbation eect is present and to what extend. Thus the
data set T is unlabeled.
In the following sections we describe an algorithm called guided clustering that
aims to detect and quantify the presence of a perturbation within tumor data sam-
ples by identifying sets of genes that are coherently expressed within T and show
strong perturbation response in G. The ndings of this work are published in the
peer-reviewed journal Bioinformatics (Maneck et al., 2011).
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4.2 Algorithm
For clarity, we rst describe guided clustering in the application context of oncogenic
pathway activation in tumor samples, and later describe a series of modications
that adapt the method to dierent applications.
In general, perturbation of a pathway will lead to either induction or repression of
its target genes. Consequently, the guiding data set G will contain genes that are up
and genes that are down regulated within the perturbed group relative to the control
group. Hence, depending on the particular gene, pathway activation is indicated by
high or low expression. To simplify computation, we multiply the expression values
of pathway repressed genes by -1 in both datasets, such that numerically all targets
display 'high' expression upon pathway activation.
4.2.1 Denition and fusion of similarity matrices
In order to nd sets of genes that are coherently expressed within T we need to dene
a measure of coherence between genes in the tumor data T . We use a correlation
based gene distance metric as suggested by Eisen et al. (1998). For any two genes g
and h the distance between g and h is dened as:
d(g; h) = 1 max ((g; h); 0) ; (4.1)
where (g; h) is the Spearman correlation between the expression vectors of genes g
and h. Spearman's correlation coecient guards against the disturbing inuence of
single outlier expression values as it converts the expression values to ranks before
the correlation is calculated. Note that anti-correlated pairs of genes are set to zero,
as we are only interested in correlated sets of genes. Anti-correlated genes have a
conicting interpretation in terms of pathway activation, since we corrected all genes
such that 'high' expression values represent pathway activation as described above.
Concerning the guiding data G there is no need to calculate all pairwise dis-
tances between genes since we are only interested in whether a gene is responding
to the pathway activation or not. Pathway responding genes are supposed to show
a dierence in expression between the group samples subject to perturbation and
the control group. Like with the pairwise gene distances in T we measure pathway
response by the correlation between a gene g and the label vector Y :
d(g; Y ) = 1 max (%(g; Y ); 0) (4.2)
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where %(g; Y ) is the Pearson correlation between the expression vector of gene g and
the label vector Y . Here Pearson's correlation coecient is used since we want to
preserve the inuence of the within class variance on the distance.
Together both distance functions implement the two objectives we are aiming
at: (i) Genes that are coherently expressed across the tumor samples will have low
pairwise distances in within T . (ii) Genes that show response to pathway activation
have low distances towards the label vector Y . We need to develop an approach
that select genes based on those two conditions simultaneously.
Based on the fact that coherently expressed genes in T are situated in close prox-
imity of each other, one can rank genes according to their proximity to neighboring
genes using kernel density estimation (KDE). An introduction into KDE can be
found in section 2.1.2. We follow this approach by applying a Gaussian function
to the pairwise distances within T . The result is a matrix AT of pairwise gene
similarities. For two genes g and h AT is dened as
AT (g; h) = exp
 d(g; h)2
22

(4.3)
where  is a smoothing parameter that allows adjustment of the smoothing band-
width as shown in Figure 4.1(a). Parameter calibration will be discussed in section
4.2.4. High row sums of AT indicate that the corresponding gene is situated in a
dense area or gene cluster.
To integrate gene response to pathway activation in the density estimation process
we transform the distances between gene expression across G and the label vector
Y similar to the pairwise distances of T . We dene a diagonal similarity matrix AG
as
AG(g; g) = exp
 d(g; Y )2
22

(4.4)
where all entries AG(g; h) with g 6= h are set to zero. High values of AG(g; g)
correspond to genes that respond to pathway activation, while genes that do not
respond strongly approach zero. Again the parameter  species the bandwidth of
the smoothing function.
The integration step is done by reweighting AT with AG using matrix multipli-
cation. We call this procedure matrix fusion:
W = A
1=2
G ATA
1=2
G ; (4.5)
39
(a) (b)
Figure 4.1: Gaussian smoothing functions transform gene distances into gene similar-
ities: (a) Parameter  inuences the smoothing bandwidth or slope of the Gaussian
function. (b) The two data sets T and G are weighted against each other by the
parameter !. The graphs show the resulting gene similarity depending on ! for
dierent choices of  for the gene distance of 0:5. Solid lines show similarity values
of AT and dashed lines values of AG.
where left and right hand side multiplication ensures symmetry of the resulting ma-
trixW that holds high values only for pairs of genes that show consistent expression
in T and simultaneously a common response to pathway activation in G.
Figure 4.2 schematically explains the eect of matrix fusion. The points in the
left panel show a set of genes embedded in the 2-dimensional plane. Their distance
reects similarity according to AT . Coherently expressed genes are situated closer
to each other. The gray tone encodes information from the guiding data. Black
points do not show dierential expression in G while gray points are targets, and
the brighter the point, the stronger the gene responds to pathway perturbation.
Note that all genes fall into clusters. This is typical for expression data. Barely
any one gene is regulated independently from any other genes. The right panel
shows the same genes again. However this time, the distances are based on the
fused similarity matrix. The dark points moved out of the clusters and distribute
uniformly. The only remaining dense areas consist of bright genes that were already
close to each other in the left panel. The eect of matrix fusion can be viewed as a
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(a) (b)
Figure 4.2: Matrix fusion induces a magnetic repulsion between genes: Each point
represents one gene. The distance between points reects the similarity of genes
while gray shades represent the genes response to pathway perturbation. The
brighter a point the stronger the gene responds to the perturbation. (a) Gene
similarities based on coexpression in the tumor data only. All genes fall in clusters,
since genes are regulated in concert. (b) The same genes as in (a), but distances are
based on the fused similarity matrix W . Genes that do not respond to the pathway
moved out of the clusters and distribute uniformly across the plane.
magnetic repulsion between genes. The less a gene responds to pathway activation,
the stronger is its repulsion from all other genes. Genes remaining in clusters are
potential pathway target genes that are consistently regulated in tumors. We will
use their consensus expression as a surrogate for pathway activity in tumors. Figure
4.2 shows that the matrix fusion induces dissimilarities that makes clustering of
genes a hard problem, since many genes are no longer in clusters but on their own.
Most available cluster methods are problematic in situation where data includes
large numbers of scattered points, as they are aiming to assign all data points to
clusters. Applying standard algorithms to such data usually results in clusters that
are skewed or misleading. Tseng and Wong (2005) suggested a resampling based
approach that partially overcomes this problem, but we will not follow this approach
here. Instead we aim to detect the top most dense modules of genes, thus leaving the
majority of genes unassigned to any cluster. A simple procedure to extract dense
sets of genes is described in the next section.
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4.2.2 Extraction of tight expression modules
Given the fused similarity matrix W and following the KDE approach, we dene
the neighborhood density K(g) for each gene as the row sum of W
K(g) =
pX
i=1
Wg;i (4.6)
where p is the total number of genes in the data set. A gene g with a high value
K(g) is located in a large and dense cluster of genes.
The module extraction procedure of guided clustering starts by selecting the gene
g0 that maximizes K(g) as a seed gene. Next a module of genes C is grown around
g0 using average linkage by iteratively adding genes gk that maximize
(g0; g1; : : : ; gk 1; gk) =
P
i;jkWgi;gj
jCj+ 1 (4.7)
where jCj is the number of genes in C. The iteration is terminated, if no gene
gk exists, such that (g0; g1; : : : ; gk 1; gk) > (g0; g1; : : : ; gk 1). In case we want to
extract more than one dense cluster, we remove all genes selected in the current
iteration, recompute K(g) and proceed as described above.
4.2.3 Condensing the joint expression of genes in a module
to a consensus expression index
Recall that our goal is to estimate pathway activation for each tumor sample of T .
By construction, the expression levels of genes in a extracted module are tightly
correlated across the tumor samples. Further, in any tumor they are either unan-
imously up or down regulated. This allows us to condense their expression into
a single number per tumor. This number can be used as a surrogate for pathway
activity in the tumor. Remember that all genes were adjusted such that numerically
all targets display 'high' expression upon pathway activation. Hence a high index
points to an active pathway and a low index to an inactive pathway. Note that
although genes in a module correlate strongly their expression values can deviate
highly due to scale dierences. A module can be composed of genes, where some
have a greater expression level than others. Simple summing or averaging of all
module genes per sample weights genes unequally according to their variance. In-
stead, we use a standard additive model that accounts for scale dierences on the
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log scale to compute the consensus index:
yij = + i + j + ij; (4.8)
where yij is the observed expression of a gene, i a gene specic scale coecient,
j the sample specic index of pathway activation and ij the error term. We t
the additive model using Tuckey's robust median polish procedure (Hoaglin et al.,
1977). In the following we will refer to the index as pathway activation index
(PAI). Note that our approach for summarizing the expression of module genes to
a PAI is identical to a method used to compute probeset summaries in the popular
normalization package RMA for Aymetrix GeneChips.
4.2.4 Balancing both data sets & parameter selection
In the last section we described a method that identies modules of genes that are
coherently expressed in T and have joint dierential expression in G. Further we
summarized the gene modules to a single index that estimates response to pertur-
bation in the tumor samples. We do not weight the inuence of the two data sets T
and G against each other. Such a weighting is necessary since the values of T and
G might be on dierent scales.
The weighting is achieved by introducing a new parameter ! to the equations 4.3
and 4.4. We extend equation 4.3 and 4.4 by:
AT (g; h) = exp
 (1  !)d(g; h)2
22

(4.9)
and
AG(g; g) = exp
 !d(g; Y )2
22

(4.10)
where ! is chosen between 0 and 1 and therefore shifts the focus from the clinical data
(! = 0) to the guiding data (! = 1). By setting ! = 0 the nominator in equation 4.10
equals zero. Hence AG becomes the identity matrix as the exponential of zero equals
one. If we plug in the identity matrix for AG in equation 4.5, W = AT since matrix
multiplication with the identity matrix is self-preserving. Likewise setting ! = 1
results in AT (g; h) = 1 for all pairs of genes g and h. Thus all entries of the fused
similarity matrix W (g; h) equal
p
AG(g; g)  AG(h; h), eliminating the inuence of
AT on the identication of gene modules. Setting ! to any value between zero and
one balances the inuence between both data sets. This balancing is illustrated by
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Figure 4.1(b). Moving the focus from T to G by increasing ! lifts the resulting
pairwise gene similarities on T and decreases the resulting per gene similarities on
G.
To select a optimal ! we need to evaluate the inuence of both data sets by some
measure. While the tumor data T is driving within cluster similarity, the guiding
data G forces genes to have a high response to perturbation. For a gene module
C! retrieved for a specic !, we evaluate the within cluster similarity by (!), the
average pairwise correlation between genes of C!:
(!) = 1=jC!j2
X
g;h2C!
max((g; h); 0) ; (4.11)
where jC!j is the number of genes in C! and (g; h) is Spearmans correlation of any
two genes g and h. The within cluster response to perturbation of a gene module
C! is assessed by the average gene activation '(!) dened as:
'(!) = 1=jC!j
X
g2C!
%(g; Y ) ; (4.12)
where % is Pearsons correlation of gene g and the label vector Y .
To select the optimal ! during gene module extraction, we generate a set of
module candidates for dierent choices of !. The parameter ! is varied from 0 to
1 in steps of 0:1. The best choice features a high within module correlation and a
high average response to perturbation. Hence we choose ! by maximizing the sum
of (!) + '(!). Since (!) and '(!) are on dierent scales we rescale them before
summation, such that they both range form 0 to 1. This means ,if ! is set to zero
(!) = 1 and '(!) = 0, since all weight is on T . In contrast if ! is set to one
(!) = 0 and '(!) = 1, since we focus only on G.
The parameter  species the bandwidth of the smoothing kernel and inuences
the global sensitivity of the method. Larger bandwidths generate higher gene sim-
ilarities as shown in Figure 4.1(b). This results in larger clusters that may include
genes with low responses to perturbation. Smaller bandwidth enforce more rigorous
restrictions on the genes from the guiding data. We recommend to tune  manually
starting from a large value and decreasing it in several steps while at the same time
monitoring the cluster tightness and the distribution of perturbation responses in
the guiding data. For our analysis we varied  between 1=3  0:33 and 0:1=3  0:03
in steps of 0:1=3  0:03. An example for parameter tuning will be given in section
4.3.2.
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4.2.5 Extensions to other experimental settings
So far, we have discussed guided clustering in the context of a gene expression based
perturbation experiment. Here the labeled guiding data set G consists of two classes
of gene expression proles: (i) The perturbed class, measuring the per gene response
of a perturbation like gene silencing by RNAi or application of a compound and (ii) a
corresponding control. Guided clustering can be easily adapted to other application
scenarios such as protein binding or interaction assays, DNA methylation studies
or genome aberration studies via array CGH. Basically it works with any method
that gives a quantitative measurement per gene. The adoption is made by tailoring
the similarity function in equation 4.10 to the application. The similarity values
need to quantitatively rank genes that should be preferentially used to build gene
clusters. The strongest preference possible is encoded by a value of 1. Smaller values
gradually reduce the inuence of a gene. The preference scores need to be calculated
from guiding data. For example the preference score can reect the connectivity of
a gene in a protein-protein interaction network, thus guiding the formation of gene
clusters seeded around hub genes. They can also reect the binding abundance of a
transcription factor assessed in a chromatin immunoprecipitation experiment thus
guiding the gene clusters to be build from targets of a specic transcription factor.
We will demonstrate the use of guided clustering in this context in section 4.4.1.
4.2.6 Runtime
To analyze the runtime of the guided clustering algorithm we dissect the algorithm
into its three main parts: (i) The calculation of the pairwise gene distance matrix
has a runtime of O(n2), where n is the number of genes. (ii) Transformation of the
pairwise gene distances into anities needs additional n! O(n
2) operations, were n!
is the number of values used for ! when choosing the optimal weighting between both
datasets. (iii) Extracting k gene modules has a complexity of k O(n). In practice,
the total complexity O(n2)+n! O(n
2)+k O(n), is dominated by the square number
of input genes n2.
All calculations have been performed on a machine containing 16 Quad-Core
AMD Opteron 8354 processors with 2.2 GHz each and 132 GB main memory. At
the current state of development guided clustering is a single thread method using
1 of 16 processors available. For the analysis of simulated data sets used in section
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4.3 each run needed 13 sec on average. Analysis of the lymphoma samples together
with BCL6 and LPS data in section 4.4.1 and 4.4.2 took about 890 and 902 sec,
respectively.
4.3 Simulations
Prior to testing guided clustering in real data integration contexts, we study its per-
formance on data that is articially generated and fullls the underlying assumptions
of our algorithm. This allows us to better understand its limitations alongside those
of competing strategies. In simulations, the data generating process denes a ground
truth, against which any analysis result can be evaluated. In real applications we
often do not have a ground truth result. Moreover, focused simulations allow us to
study individual diculties in the analysis independently from each other, while real
data usually comprises many of them in parallel. Finally, the diculty of clustering
problems can be scaled freely in simulations. In this section we compare guided clus-
tering to the two competing sequential analysis concepts described in the literature
which select genes sets only using the clinical (Läuter et al., 2009) or the guiding
data respectively (Bild et al., 2006).
4.3.1 Simulation model
We simulate articial data that mimics the application of guided clustering in the
context of pathway activation prediction via guiding by perturbation experiments.
The data consist of an articial clinical data set T with 80 samples and a guiding
data set G with 20 control and 20 perturbed samples. The data sets comprise 1500
features. Both data sets are generated by adding a signal component Fij or Iij and
a noise component ij:
Tij = Fij + !T ij (4.13)
and
Gij = Iij + !G ij (4.14)
The components Fij and Iij contain the ground truth, since they simulate the target
signals, while the noise components ij simulate technical measurement uctuations
and biological variability not related to the target signal. The tuning parameters
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!T and !G are used to calibrate the signal-to-noise ratio. The noise component is
simulated for both data sets using a multivariate normal distribution with a block
structured covariance matrix  as proposed by Guo et al. (2007):
 =
0BBBBBBB@
k 0 0 0 0
0  k 0 0 0
0 0 k 0 0
0 0 0  k 0
0 0 0 0 k
1CCCCCCCA
10001000
(4.15)
with
k =
0BBBBBBBB@
1 k : : : k98 k99
k 1
. . . . . . k98
...
. . . . . . . . .
...
k98
. . . . . . . . . k
k99 k98 : : : k 1
1CCCCCCCCA
100100
(4.16)
where k reects the amount of co-regulation, similar to Guo et al. (2007) we set
k = 0:9.  is a square matrix with the number of genes as dimensions and has a
block structure. Each block has the dimensions 100 100 and represents one set of
co-regulated genes.
For Tij we generate signals in 3 clusters E1; : : : ; E3 of 200 features each repre-
senting dierent biological activities across the samples. In analogy to the additive
model we generate traces of pathway activity by drawing for each gene in a clus-
ter a random number i uniformly from the interval [0; 1]. This number represents
the strength with which a gene responds to pathway activation. Moreover, for every
sample we draw a uniformly distributed random number j from the interval [ 1; 1],
which represents the strength of the pathway activation in this sample. Fij is then
set to i + j. Note that since clusters mimic dierent biological activities, j is
constant throughout genes from the same cluster but not for genes from dierent
clusters. For genes that do not fall in any of the three clusters Fij is set to zero.
The simulation of the guiding data Gij includes a set Bd of 600 responding genes.
These genes are simulated dierently for control and perturbation samples. For each
of them we draw a random number i uniformly from [0; 1] and set Iij =   for
control samples and Iij =  for perturbation samples. For the remaining genes, we
set Iij to zero. The size of the intersection of the three clusters Ei with the set of
responding genes varies across clusters (200 for E1, 100 for E2, and 50 for E3).
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Signal-to-noise ratios are not constant over genes but we can use the tuning
parameters !T and !G to calibrate the max signal-to-noise ratios
R = max
i

rmsd(Fi;)
rmsd(i;)

(4.17)
where the maximum is taken over all genes and the root mean square distance (rmsd)
of a gene expression vector is dened as
rmsd(x) =
vuut 1
n
nX
j=i
(xj   x)2 (4.18)
where n is the number of samples in T . In our simulations we varied R for T between
2 and 0:5 in steps of 0:1. In the guiding data G the maximal signal to noise ratio
was kept constant at 2. For each signal-to-noise setting 20 data sets were generated.
The simulation setup is summarized in Figure 4.3(a) and an exemplary data
set with signal-to-noise ratio of 1 is shown in Figure 4.3(b). Note that we not
only simulate signals and noise but also confounding structures including clusters
of correlated genes in T that do not correspond to induced genes in G as well as
induced genes in G that do not form tight clusters in T .
4.3.2 Simulation analysis
In this study we want to assess the performance of guided clustering reconstructing
the hidden pathway activation signals j for all samples and all three clusters. We
compare guided clustering to two possible sequential analysis concepts, namely gene
selection based on experimental data followed by pathway activity prediction on the
clinical data as described by Bild et al. (2006), and gene selection via identication
of strongly correlated gene sets in the clinical data followed by multivariate tests in
the experimental data as described by Läuter et al. (2009).
We ran guided clustering on a series of simulated data sets with increasing dif-
culty. To evaluate accuracy of the estimated signals, we calculated the maximal
correlation of the top 3 estimated pathway indices ^j to any of the j underlying
the simulation. For each signal-to-noise setting we averaged the accuracy across the
20 simulated data sets.
The whole simulation study includes 320 independent runs of guided clustering.
As an example we give a detailed description of analysis results obtained for a
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(a) (b)
Figure 4.3: (a) Structure of the simulated data. The three clusters with non-zero
signals Fij in T are named E1, E2 and E3. Each eect overlaps with a certain number
of dierentially expressed genes in Bd  Gd. The overlaps are named O1, O2 and
O3. (b) Example of simulated data with signal-to-noise ratio set to 1. Dierent
simulated eects are indicated by left side colorbar: red - O1, blue - O2, green - O3,
orange - Gd =2 O1 [ O2 [ O3, dark blue - E2 =2 O2, dark green - E3 =2 O3. Tumor
samples (T ) and guiding data samples (G) are indicated by a colorbar on top: red
- T and blue - G.
signal-to-noise ratio of 1. The analysis starts with calibrating the parameter , such
that the resulting modules are highly enriched for genes with strong perturbation
responses within the guiding data. We begin with a large value of  = 0:33 and
consecutively lower it while monitoring the distribution of signals from the guiding
data. Figure 4.4 illustrates the selection process, with  = 0:23 a good balance was
found. All extracted modules show strong responses to the perturbation. We kept
 = 0:23 constant for all other analyzes.
Both sequential analysis concepts were evaluated similar to guided clustering.
For the approach described by Bild et al. (2006) we employed the limma package
to rank the genes according to their dierential expression within the guiding data.
The top 100 dierentially expressed genes were used to estimate the perturbation
response of the tumor samples by tting the additive model described in section
4.2.3. Correlation with the simulated eects was calculated as described above.
The concept described by Läuter et al. (2009) works in the opposite direction by
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Figure 4.4: Guiding strength of top three clusters extracted with dierent choices
of .
selecting clusters of genes highly correlated across T . Those gene clusters are then
tested for joint dierential expression in G. We assume that we have an optimal
cluster algorithm at hand and use the correct simulated gene clusters to estimate
the perturbation response in the tumor samples by tting the additive model. The
gene clusters are tested for joint dierential expression in G using the geneSetTest
function of the limma package. This function tests whether a set of genes is highly
ranked relative to other genes in terms of a given statistic. We used the t-statistic
supplied by the dierential gene expression analysis of limma.
Figure 4.5(b) shows the performance of guided clustering and both sequential
approaches on estimating the perturbation response within the tumor samples of
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(a) (b)
Figure 4.5: (a) Trade-o between within cluster correlation and guiding strength
depending on !. (b) Accuracy of estimated eects depending on the signal-to-noise
ratio with   0:23: black - guided clustering; red - Läuter et al.; green - Bild et
al.; E1; E2; E3 simulated eect with 200; 100; 50 genes overlapping between induced
perturbation in T and dierential expression in G.
the three simulated eects (E1 solid, E2 dotted, E3 dashed line). Guided clustering
reconstructs the pathway indices correctly for signal-to-noise ratios  1. However,
the smaller the overlap between the correlated clusters in T and the dierentially
expressed genes in G the more dicult the reconstruction. The approach by Läuter
et al. (2009) reconstructs the signals perfectly since we provided it with the correct
gene sets. Using the approach of Bild et al. (2006) results in a poor reconstruction
quality. The method is only able to coarsely reconstruct the cluster with the biggest
overlap. We believe that the ignorance of the correlation structure in T that this
method exercises when constructing gene sets compromises its performance in signal
reconstruction.
To determine whether gene modules showed a signicant grade of perturbation
response we employed the geneSetTest function of the limma package as described
above. We tested only modules identied by guided clustering or the approach of
Läuter et al. (2009), since gene modules identied by the approach of Bild et al.
(2006) are signicant per se as they involve only the 100 top ranking genes. Table
4.1 shows how often a gene module was considered to be statistically signicant given
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Table 4.1: Percentage of simulation runs in which the identied gene sets were rated
as signicantly dierent within the guiding data G for varying signal-to-noise ratios.
The signicance threshold was set to 0.05 (0.01).
guided clustering tumor clustering
snr cluster 1 cluster 2 cluster 3 cluster 1 cluster 2 cluster 3
0.5 1.00 (1.00) 1.00 (0.95) 1.00 (1.00) 1 (1) 0.85 (0.40) 0 (0)
0.6 0.95 (0.95) 0.95 (0.85) 1.00 (1.00) 1 (1) 0.75 (0.25) 0 (0)
0.7 0.95 (0.80) 0.95 (0.80) 0.95 (0.90) 1 (1) 0.80 (0.30) 0 (0)
0.8 1.00 (1.00) 1.00 (0.95) 0.90 (0.85) 1 (1) 0.65 (0.45) 0 (0)
0.9 1.00 (0.90) 1.00 (1.00) 1.00 (0.95) 1 (1) 0.70 (0.30) 0 (0)
1.0 1.00 (0.95) 0.95 (0.80) 1.00 (0.80) 1 (1) 0.75 (0.40) 0 (0)
1.1 1.00 (0.95) 1.00 (1.00) 0.95 (0.95) 1 (1) 0.85 (0.35) 0 (0)
1.2 1.00 (1.00) 1.00 (0.95) 1.00 (0.95) 1 (1) 0.65 (0.40) 0 (0)
1.3 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.85 (0.50) 0 (0)
1.4 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.60 (0.45) 0 (0)
1.5 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.85 (0.50) 0 (0)
1.6 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.70 (0.35) 0 (0)
1.7 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.80 (0.30) 0 (0)
1.8 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.85 (0.45) 0 (0)
1.9 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.55 (0.20) 0 (0)
2.0 1.00 (1.00) 1.00 (1.00) 1.00 (1.00) 1 (1) 0.75 (0.35) 0 (0)
a threshold of 0:05 or 0:01, respectively. Guided clustering reliably detects gene sets
with dierential expression in G for both thresholds. For low signal-to-noise ratios
the performance is slightly worse. In comparison, the approach of Läuter et al.
(2009) identies perturbation response only in gene modules were the majority of
contributing genes are dierentially expressed (cluster 1). Modules were only half of
the genes (cluster 2) or less (cluster 3) are dierentially expressed within the guiding
data were detected only sometimes or never.
In summary, guided clustering cannot outperform the sequential methods both
with respect to cluster tightness and enrichment of genes with strong signals from
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the guiding data. However, conversely it is the only method that can achieve good
performance in both aspects simultaneously.
4.4 Applications
The guided clustering procedure identies gene modules that respond strongly to
the perturbation present in the experimental data while at the same time display
coherent expression in clinical expression proles. This general setting allows the
application of guided clustering in many dierent situations. In this thesis we present
two of them: (i) The detection of functional targets of a transcription factor and
the quantitative estimation of its activity in individual clinical samples, and (ii) the
estimation of pathway activities in tumor samples as introduced by Bild et al. (2006)
using a cell line stimulation experiment. All lab work concerning the stimulation
experiment was done by our cooperation partners from the laboratory of Dieter
Kube from the university clinic for hematology in Göttingen.
4.4.1 Identication of BCL6 target modules in diuse large
B-cell lymphomas
BCL6 is a key oncogene in B-cell lymphomas The transcription factor BCL6
acts predominantly as a repressor of transcription. In B-cells, BCL6 is required
for the formation of germinal centers (GC). Hence its function is critical for the
working of the acquired immune system. It was shown by Dent et al. (1997) and
Ye et al. (1997) that BCL6-null mice lack the formation of GC and are unable to
produce high-anity antibodies. In diuse large B-cell lymphomas (DLBCL) BCL6
is frequently translocated, hyperpermutated or hypermethylated. In fact, the BCL6
gene was identied in 1993 as the target of chromosomal translocations in DLBCL
by Baron et al. (1993), Ye et al. (1993a) and Ye et al. (1993b). Its oncogenic po-
tential was shown by Cattoretti et al. (2005) in mouse models where deregulated
BLC6 expression lead to the development of lymphomas. It is assumed that this
dysfunctional activity contributes to oncogenesis in a subset of DLBCL and poten-
tially also in dierent malignancies (Iqbal et al., 2007). DLBCL is a morphologically,
genetically and clinically heterogeneous lymphoma entity (IARC, 2008) with sev-
eral dened subentities (Rosenwald et al. (2002), Bentink et al. (2008)). Whether
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dierential BCL6 activity contributes to the heterogeneity is not fully known.
The inuence of BCL6 on the transcriptional program of B-cells is accomplished
via BCL6 targeted genes. The identication of such target genes is essential for
understanding the underlying mechanisms of transcriptional regulation. Initially,
BCL6 target discovery was based on educated guesses (Niu et al., 2003) and gene
expression proling (Shaer et al., 2000). Recently, Polo et al. (2007), Ci et al.
(2009) and Basso et al. (2010) identied large sets of genes whose promotor regions
are bound by BCL6 in vivo. Ci et al. (2009) generated a data set by performing
a ChIP-on-chip screen with primary human GC B-cells and the DLBCL cell lines
OCI-Ly1 and OCI-Ly7 using high density oligonucleotide promotor microarrays.
This data was combined with gene expression proles from DLBCL. The authors
followed a strictly sequential analysis strategy: (i) Only the ChIP data was used to
identify distinct groups of genes bound by BCL6 exclusively in GC B-cells, DLBCL,
or both. (ii) A look up of these genes in a tumor data set revealed that a large number
of BCL6 target genes are silenced in primary human centroblasts compared to naive
B-cells. But only half of those genes are also silenced in DLBCL. Among these non-
silenced genes are critical mediators of survival, growth, proliferation and B-cell
dierentiation. Hence Ci et al. (2009) reason that the transcriptional programming
of BCL6 is disturbed in DLBCL. Further, BCL6 target genes have a lower expression
in GC B-cell-like (GCB) lymphomas compared with activated B-cell-like (ABC)
lymphomas. In their analysis the authors considered DLBCL and its subentities
GCB and ABC as lymphoma populations. They did not account for variability of
BCL6 target expression across individual lymphomas. In fact, we observed that the
expression of the top ranking genes in DLBCL is rather disperse (Figure 4.6(a)).
Genomewide chromatin immunoprecipitation assays identify binding sites of tran-
scription factors in the neighborhood of genes and thus generate lists of potential
targets of this transcription factor. Clearly, binding does not imply regulation. In
general, several regulators and cofactors are needed for transcription and their pres-
ence depends on the cellular context. In the BCL6 context, various cofactors have
been identied by Dhordain et al. (1997), Dhordain et al. (1998), Huynh and Bard-
well (1998), Huynh et al. (2000), Lemercier et al. (2002) and others. However, if a
transcription factor like BCL6 actively regulates a module of target genes in a de-
ned cellular context like the DLBCL context, its functional targets should display
correlated expression across clinical samples. The heterogeneity of DLBCL poses
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an additional problem, since it is not clear whether there is only a single 'DLBCL
context'. The expression and activation of transcriptional co-regulators might vary
across DLBCL and we might nd multiple modules of functional BCL6 targets, each
expressed in dierent subsets of DLBCL.
Data In our analysis we used guided clustering to integrate the BCL6 ChIP-on-
chip data of puried GC B-cells from Ci et al. (2009) with 220 expression proles
of DLBCL and Burkitt lymphoma samples from Hummel et al. (2006). Both data
sets were taken from the Gene Expression Omnibus (Edgar et al., 2002), GEO-
accession: GSE15179 and GSE4475. Gene expression proles were measured on the
Aymetrix HG-U133A GeneChipTMplatform and the variance stabilization method
proposed Huber et al. (2002) was used for normalization. All probe sets were sum-
marized to gene expression values by tting a standard additive model, employing
Tuckey's median polish algorithm (Hoaglin et al., 1977). The ChIP-on-chip data was
available as normalized log2 ratios per gene locus representing the binding anity
fold change between sample and corresponding control. We averaged the log2 ratios
across all three replicates after truncating ratios above the 95% quantile of all pos-
itive log2-ratios ( 2:67). Locus by locus we subtracted the log2 ratios from their
maximum across samples and fed these values directly into the guided clustering
algorithm. The BCL6 binding loci were matched to HG-U133A probe sets using
the accession numbers and NCBI reference sequence (refseq) identiers provided by
Ci et al. (2009). Multiple probe sets for the same locus were summarized using the
median polish algorithm. Each of the nal data sets consisted of 9648 genes.
Result On this data sets, we ran guided clustering and identied the top three
modules of BCL6 targets each expressed predominantly in a dierent subset of
lymphomas. The smoothing parameter  was selected as described in section 4.2.4
and set to  = 0:23. The selection process is illustrated in Figure 4.7.
We extracted the top three gene modules. Their expression across the lymphoma
samples is shown in Figure 4.6(e). Within each module the genes are coherently
expressed and there is a continuous gradient when the samples are ordered by in-
creasing BCL6 indices. All module genes exhibit strikingly large log2-ratios as shown
in Figure 4.6(b), indicating that BCL6 indeed binds their promotor. Together both
plots conrm that the two data sets are in good balance. In agreement to the ob-
servations of Ci et al. (2009) the second extracted index (BCL6-index2) is higher in
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Table 4.2: Cox-regression analysis of DLBCL depending on the BCL6-index2, ad-
justed for activated B-cell (ABC) status, age and Ann Arbor staging.
factor p-value relative risk (95% condence interval)
BCL6-index2 3.40e-6 *** 0:0257 (0:0055  0:1205)
ABC-status 0.02298 * 2:2112 (1:1157  4:3823)
Ann Arbor stage 0.00173 ** 3:1389 (1:5347  6:4203)
age 0.27981 1:4352 (0:7453  2:7634)
ABC than GCB type DLBCL (P < 10 9, t-test).
To test for a clinical impact of BCL6 activity in DLBCL we tted a cox pro-
portional hazard model including the BCL6-index from module 2 as a continuous
covariate together with the established categorical prognostic factors ABC/GCB
status, age > 59 years, and Ann Arbor staging. Our survival analysis was restricted
to a group of patients that received identical treatment, a combination of chemother-
apy based on cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
or similar. This was the case for 80 lymphoma patients in the study. We found
the BCL6-index2 to be a signicant independent predictor of survival (P < 10 5).
Patients with a high BCL6-index2 have a better outcome than patients with a low
index. Notably, the hazard associated with the BCL6-index2 is higher than all other
factors including the ABC/GCB status as shown in Table 4.2.
The BCL6-index2 accumulates the expression of 335 genes including several BCL6
targets that where also described in the primary analysis of the data by Ci et al.
(2009) like the oncogenes BCL2A1, CCND1, CCND2, HSP90B1 and JUNB, as well
as the transcription factors STAT1 and STAT3. A full list of all genes can be
found in supplementary Table 6.1. We analyzed this gene set for enrichment of
genes involved in certain aspects of B-cell functionality or malignant transformation
using the Gene Set Analysis Toolkit V2 by Duncan et al. (2010). Genes involved in
Toll-like receptor signaling were signicantly enriched (P < 0:004, hypergeometric
test). Similarly we found enrichment of Jak-STAT signaling genes (P < 0:001,
hypergeometric test). These observations support the ndings of Basso and Dalla-
Favera (2010), who hypothesize that BCL6 modulates signaling through Toll-like
receptors.
56
(a) (b) (c) (d)
(e) (f)
Figure 4.6: (a, c) Gene expression of top 100 genes with highest BCL6 binding fold
change (a) or LPS activation (c), respectively. Yellow indicates high and blue low
expression. The samples were ordered according to their mean expression. (b, d)
BCL6 binding fold change (b) or LPS activation (d) of the extracted gene clusters
compared to non cluster genes. (e, f) Gene expression of extracted PAI gene clusters
across the lymphoma samples (1st - red, 2nd - blue, 3rd - green). Samples are ordered
increasingly with respect to the PAI. On top of each gene cluster the two other PAIs
are shown. Yellow indicates high and blue low expression.
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Figure 4.7: Guiding strength of top three BCL6 clusters extracted with dierent
choices of . For   0:23 the extracted clusters show outstanding high BCL6 fold
changes.
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4.4.2 LPS mediated Toll-like receptor signaling and BCL6
targets are coherently expressed in DLBCL
Data We follow-up our results from the previous section and support the hypoth-
esis of Basso and Dalla-Favera (2010) by stimulating Toll-like receptors directly in
the lymphoma cell line BL-2. The stimulation is achieved by treating the cells for 6
hours with lipopolysaccharide (LPS). Toll-like receptor mediated signal transduction
of LPS stimulation has been shown by Chow et al. (1999) and Schwandner et al.
(1999). In our experiment we compared expression proles of stimulated cells with
control proles of unstimulated BL-2 cells. The expression proles were generated
on the Aymetrix HG-U133plus2.0TMplatform. Data normalization was performed
as described in section 4.4.1. Only the subset of genes that was also represented
within the lymphoma and BCL6 data sets was used for further analysis. Altogether
6 samples were hybridized, 3 independent biological replicates in each group. A
detailed description of the sample preparation can be found in the supplementary
material section 6.5.
Result We used guided clustering for a joint analysis of our stimulation data
and the lymphoma data set by Hummel et al. (2006). This is a typical applica-
tion of guided clustering in the context of integrating experimental cell perturbation
data and clinical expression studies. In contrast to ChIP assays, cell perturbation
experiments can identify functional targets of signaling pathways. However, they
are not conned to direct targets. Transcriptional regulation is context specic and
the molecular contexts of a cell culture signicantly diers from that of a tumor.
Nevertheless, if genes whose expression respond in the cell culture context also dis-
play a coherent expression across patient proles, it is likely that their consensus
expression reects the activity of this pathway in individual patient probes as shown
by Bentink et al. (2008). We applied guided clustering to identify transcriptional
modules that are conserved between both cellular contexts. The smoothing param-
eter  was selected as described in section 4.2.4 and set to  = 0:17. Figure 4.8
illustrates the selection process. As in the BCL6 analysis, we extracted the top 3
modules and examined them for cluster tightness in the lymphoma data and joint
dierential expression in the guiding data. Figure 4.6(f) shows heatmaps of the ex-
tracted gene modules on the clinical data. The genes are coherently expressed across
the lymphomas and form a continuous gradient when the samples are arranged by
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Table 4.3: Cox-regression analysis of DLBCL depending on the LPS-index2, ad-
justed for activated B-cell (ABC) status, age and Ann Arbor staging.
factor p-value relative risk (95% condence interval)
LPS-index2 9.48e-7 *** 0:0257 (0:0059  0:1110)
ABC-status 0.01170 * 2:4722 (1:2231  4:9970)
Ann Arbor stage 0.00132 ** 3:2994 (1:5927  6:8350)
age 0.27995 1:4355 (0:7451  2:7657)
increasing LPS indices. The distribution of correlations to the class label vector for
module genes and non-module genes are shown in Figure 4.6(d). The module genes
stand out and are clearly enriched for LPS stimulation.
Strikingly the LPS-index2 and BCL6-index2, although derived from completely
dierent guiding data sets are almost perfectly correlated (r >0:98). Both gene
modules, including 335 (BCL6) or 198 (LPS) genes, overlap only in 73 genes. A
complete gene list of the LPS-index2 can be found in supplementary Table 6.2 it
contains prominent oncogenes like BCL2A1 and the transcription factor STAT1
which were previously described as BCL6 targets by Ci et al. (2009). Furthermore
tting a Cox-regression model including established prognostic factors as described
above showed that LPS-index2 is an independent highly signicant predictor of
survival. The associated hazard is higher than all other included prognostic factors
as shown in Table 4.3.
This further supports the hypothesis of Basso and Dalla-Favera (2010) that BCL6
in fact modulates Toll-like receptor signaling in DLBCL.
4.5 Discussion
In this chapter we introduced guided clustering, a novel method for the combined
analysis of clinical microarray gene expression data and experimental data. in con-
trast to completing analysis strategies, guided clustering does not analyze the two
data sets sequentially, but in a single joint analysis.
In a simulation study guided clustering behaves favorable compared to sequential
analysis approaches. These approaches use only one of the two data sets for the
gene selection procedure, disregarding the structure or constrains of the second data
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Figure 4.8: Guiding strength of top three LPS clusters extracted with dierent
choices of . For   0:17 the extracted clusters show outstanding high LPS stim-
ulation response.
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set. Our study showed that guided clustering is superior to sequential methods in
situations when both data sets should have similar inuence on the gene selection
process. The method of Läuter et al. (2009) misses gene modules were only the
minority of genes show response to perturbation, while the approach of Bild et al.
(2006) only works correctly if the top responding genes form a cluster on the clinical
data. Further guided clustering is more versatile and can integrate various kinds
of guiding data, while the other approaches only focus on gene expression data.
Our performance analysis showed that guided clustering favors bigger gene modules
that show strong responses. Smaller gene modules with weak responses are also
detectable, but will appear later in the cluster extraction process.
In this work we applied guided clustering in the context of a DLBCL study that
was guided to focus on aspects of BCL6 and Toll-like receptor signaling. We es-
tablished a novel prognostic index which holds more prognostic information than
existing predictors of survival. The composition of the genes underlying this index
point to a link between BCL6 activity and Toll-like receptor signaling. This link
was also suggested by Basso and Dalla-Favera (2010). Among the underlying genes
were known oncogenes and transcription factors that were described as BCL6 tar-
gets by Ci et al. (2009). We experimentally strengthened the link between BCL6
and Toll-like receptors by a LPS stimulation experiment combined with a second
guided clustering analysis. We observed that targets of LPS mediated Toll-like re-
ceptor signaling and BCL6 targets are coherently expressed in a large collection
of DLBCL suggesting that BCL6 in fact inuences the transcriptional program by
Toll-like receptor signaling in DLBCL.
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Part III
Analysis of Single Cells
63
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This part explores the prospects of gene expression proling of single cells using mi-
croarray technology.
In chapter 5 we investigate the application of the Operon microarray platform to
samples derived from single cells. In doing so we investigate dye specic eects
within both available channels and determine the reproducibility of biological dif-
ferences between samples. Further we compare the performance of dierent nor-
malization methods in the context of sensitivity, classication and dierential gene
expression.
An application of single cell microarray analysis is given in chapter 6, where we
investigate if embryonic pre-patterning is present in mice. We adopt the standard
nearest shrunken centroids classier to the scenario of paired samples. Further we
develop a new strategy to detect conserved mRNA asymmetries within paired expres-
sion proles.
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Chapter 5
Evaluation of single cell microarray
analysis using spike-in probes
High density oligonucleotide expression arrays proved to be a valuable tool in modern
molecular biology. The gene expression microarray delivers a snapshot of the entire
transcriptome of a tissue sample. Generally gene expression microarray experiments
are performed on tissue samples consisting of several thousands of cells. Hence, the
measured transcriptome abundances are an average across all cells of a sample.
Recently, the analysis of single cells has moved into the focus of cancer research.
For instance, the model of early metastatic spread suggests that single tumor cells
disseminate from the primary tumor in a very early stage of disease and may cause
metastasis, even if the primary tumor is removed early as reported by Hüsemann
et al. (2008). For a better understanding of the relation between disseminated tumor
cells and metastasis microarray experiments seem promising. Another example for
the use of single cell gene expression analysis is the area of reproductive medicine and
embryogenic research were the properties of specic single cells are of importance.
We will have a closer look on the application of gene expression microarrays in
the context of embryogenesis in chapter 6. However, applying the gene expression
microarray technology to single cells raises new challenges. The amount of mRNA
available in one cell is small and needs additional amplication. Each amplication
step introduces technical noise which exacerbates data analysis. Moreover, since
each sample consists only of one single and not thousands of cells the measured
expression levels are not averaged across cells, but represent the transcriptome of
one cell. Hence, samples contain not only the biological variance between dierent
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individuals but also the cellular variance within each individual. Latest research
suggests that mRNA transcription within a cell is not a continuous but a rather
stochastic process (Raj et al. (2006) and Raj and van Oudenaarden (2008)). This
means that even mRNA proles of cells from the same tissue of one patient may
exhibit large dierences.
In this chapter we will examine the prospects of microarray technology in the
context of single cell analysis. We generated a spike-in data set using the Operon
GeneChip platform. Dierent data normalization methods are compared and the
ability of dierential gene expression analysis and classication of dierent biological
backgrounds examined.
5.1 Preliminary experiments
The Operon GeneChip is a 2-channel cDNA platform and available for dierent
species like human and mouse. Before we created the spike-in data set to compare
dierent normalization procedures, we performed two preliminary experiments an-
alyzing the properties of the Operon platform. The rst experiment was a color
switch experiment including two arrays. The second experiment was based on the
results of the color switch and investigated the reproducibility of fold changes within
both channels. All data was background corrected using the normexp function of
the limma package. Subsequently the data was log2 transformed.
5.1.1 Color switch
The color switch experiment consisted of two microarrays where the same amplied
sample was hybridized against a common reference. However, while on one array the
reference was hybridized to the Cy3 (green) and the cell to the Cy5 (red) channel,
the other array was color switched. Thus the reference was hybridized to the Cy5
and cell to the Cy3 channel. This setup allows to investigate dye bias, which is the
intensity dierence between samples labeled with dierent dyes, that is attributable
to the dyes instead of the gene expression in the samples. In Figure 5.1(a) and 5.1(d)
the Cy3 channel of an array is plotted against the corresponding Cy5 channel. Both
Figures show a banana like shape indicating dierences between the intensities.
Note that both Figures exhibit the same dependence between the Cy3 and Cy5
channel although the sample types are switched between the axes. Figures 5.1(b)
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and 5.1(e) show the dye dependent dierence clearer. Even if two samples of the
same type are plotted against each other and only the dye diers, the banana shape
is present. This indicates that the dierence between the intensities that cause the
banana shape are due to the dye and not the probe type. The channels with similar
dyes were plotted against each other in Figures 5.1(c) and 5.1(f). Compared to the
other plots the intensities show a high correlation. This means that intensities from
the same channel of dierent arrays are more alike than intensities from similar
samples hybridized to dierent channels. Additionally, the dynamic range of the
two channels is dierent. While the Cy5 channel shows intensities on the full range
(0-15) the Cy3 channel agglomerates the majority of spots in an area of (5-10).
This experiment exhibit a strong dye bias and dierences in the dynamic range of
the two channels of the Operon GeneChip. At this point we are unsure if the 2-color
setup of the Operon platform is suitable for the analysis of single cells. Therefore we
performed an experiment to investigate the reproducibility of fold changes within
the two channels.
5.1.2 Conservation of fold changes
To analyze the conservation of fold changes by the two dierent channels of the
Operon GeneChip platform we performed an experiment consisting of three mi-
croarrays. Each of the three samples that were hybridized contained 20 dierent
mRNA fragments with dened copy numbers that were spiked into the hybridiza-
tion solution. These mRNA fragments bind to specic control spots on the Operon
GeneChip. The copy numbers dier between the arrays as shown in table 5.1. The
intensity values of the corresponding probes of the microarrays should reect copy
numbers changes of the sample sequences. Figures 5.1(g) and 5.1(h) show the com-
parison of the expected and observed fold changes for the Cy5 and Cy3 channel.
To evaluate the quality of fold change reproducibility more formally, we t a linear
model to the spike in probes
fcobs = 0 + 1fcexp +  (5.1)
where the observed fold change is a linear function of the expected fold change. The
ideal result would be a line with slope 1. The resulting slopes for the Cy5 and Cy3
channel are 0.21 and 0.10 respectively. However, if the three highest and lowest
expected fold changes were excluded from the analysis the slope of the Cy3 channel
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drops to 0.03 while the slope of the Cy5 channel remains at 0.21. This shows that
the Cy3 channel is not able to capture the spike-in fold changes while maintaining
the linear dierences. In contrast the Cy5 channel detects the spike-in fold changes.
But also the Cy5 channel decreases the fold changes about a factor of 1
0:21
 4:5. In
all following experiments we will employ the Operon GeneChip platform in a single
channel setup using the Cy5 channel only.
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Table 5.1: Estimated copy number per spike-in oligo (log2) used to determine the
conservation of fold changes within the Cy5 and Cy3 channel.
Cy5 Cy3 fold change
oligo id A-1 A-2 A-3 A-1 A-2 A-3 Cy5 Cy3
AF159801 26.95 8.94 8.94 8.94 26.95 26.95 -18.01 18.01
opHsV04TC000049 26.25 9.41 9.41 9.41 26.25 26.25 -16.84 16.84
opHsV04TC000044 25.71 10.05 10.05 10.05 25.71 25.71 -15.66 15.66
opHsV04TC000045 23.89 10.83 10.83 10.83 23.89 23.89 -13.05 13.05
ATU91966 23.14 12.56 12.56 12.56 23.14 23.14 -10.58 10.58
opHsV04TC000002 22.55 13.15 13.15 13.15 22.55 22.55 -9.39 9.39
opHsV04TC000001 20.83 13.89 13.89 13.89 20.83 20.83 -6.94 6.94
AF168390 20.04 15.73 15.73 15.73 20.04 20.04 -4.31 4.31
AF159803 19.40 16.27 16.27 16.27 19.40 19.40 -3.13 3.13
X56062 18.92 16.96 16.96 16.96 18.92 18.92 -1.96 1.96
opHsV04TC000004 16.96 18.92 18.92 18.92 16.96 16.96 1.96 -1.96
opHsV04TC000005 16.27 19.40 19.40 19.40 16.27 16.27 3.13 -3.13
AF191028 15.73 20.04 20.04 20.04 15.73 15.73 4.31 -4.31
AF198054 13.89 20.83 20.83 20.83 13.89 13.89 6.94 -6.94
opHsV04TC000009 13.15 22.55 22.55 22.55 13.15 13.15 9.39 -9.39
opHsV04TC000008 12.56 23.14 23.14 23.14 12.56 12.56 10.58 -10.58
AF247559 10.83 23.89 23.89 23.89 10.83 10.83 13.05 -13.05
X58149 10.05 25.71 25.71 25.71 10.05 10.05 15.66 -15.66
opHsV04TC000052 9.41 26.25 26.25 26.25 9.41 9.41 16.84 -16.84
opHsV04TC000051 8.94 26.95 26.95 26.95 8.94 8.94 18.01 -18.01
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(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 5.1: (a-f) Scatter plots of color switch experiment: Array1 has sample mRNA
on the Cy5 and reference mRNA on the Cy3 channel, while array2 is vice versa.
(g,h) Scatter plot expected vs. observed fold changes between spike-in oligos mea-
sured on the (g) Cy5 channel and (h) Cy3 channel.
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5.2 Comparison of normalization methods
Normalization is needed when dealing with multiple microarrays. Between dierent
arrays there exist two types of variation: biological variation and distracting varia-
tion. Researchers are interested in the biological variation and not in the distracting
variation, which can have multitudinous sources. The purpose of normalization is to
reduce the distracting variation, while conserving the biological. Many normaliza-
tion procedures have been proposed and compared in the literature (Bolstad et al.
(2003), Irizarry (2003)). However none of those have been applied to single cell
data. Therefore we used dierent normalization procedures and compared their in-
uence on our analysis results. We focus on three established algorithms namely
loess normalization as proposed by Yang et al. (2002), quantile normalization, which
was proposed by Bolstad et al. (2003) and variance stabilization normalization (vsn)
proposed by Huber et al. (2002). While quantile normalization and vsn can be di-
rectly applied to the data, loess normalization needs a baseline towards each array
is normalized. We dened this baseline as the median expression per gene across all
arrays of our dataset. Additional we combined loess with the quantile normaliza-
tion by applying quantile normalization to the expression ratios given by the loess
method. Prior to data normalization background correction of the spot intensities is
possible. Since it is unknown whether background correction is advantageous or not,
we performed all normalization methods with and without background correction.
If background correction was applied, we used the normexp background correction
method as recommended by Ritchie et al. (2007). The exception is vsn which we ap-
plied directly to the raw data, since this method has a build in background correction
model. Altogether we compared 9 normalization procedures: none, quantile, loess,
loess-quantile, all with and without background correction and vsn. All methods
were used as implemented in R employing the packages limma (Smyth and Speed,
2003) and vsn (Huber et al., 2003).
5.2.1 Experimental setup
To properly analyze the gene expression measurements in terms of sensitivity, sta-
bility, classication and dierential expression, data for which we know the truth is
required. Assessments can only be performed where specic results are expected.
Therefore we generated a spike-in data set consisting of 40 samples derived from two
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dierent cell lines, namely Cal51 and T47D, contributing 20 samples each. Whereas
the Cal51 samples were single cells the T47D samples were single cell equivalents
derived from a 20 cell pool. Each cell line consist of two sample types, activated and
arrested cells. Altogether the data set consists of four groups with 10 samples each:
Cal51 activated, Cal51 arrested, T47D activated and T47D arrested. Likewise to
the experiment described in section 5.1.2 20 unique mRNA fragments were spiked
into the hybridization mixture. These fragments originate from as dierent species
(Arabidopsis Thaliana) and hence do not interfere with the sample mRNA. Within
each of the 4 sample groups the spike-in concentrations were arranged in a 20 10
cyclic Latin square, with each concentration appearing one per row and twice per
column as showed in table 5.2.
5.2.2 Reproduction of spike-in concentrations and fold changes
To determine the quality of the spike-in probes we examined if the spike-in spot
intensities increase proportional to the spike-in concentrations. Figure 5.2(a) shows
average log2 intensities of the spike-in probes given a certain concentration. The
log2 intensities increase with higher spike in concentrations. Background corrected
intensities are lower than uncorrected ones. This eect especially aects lower and
diminishes with higher intensities since background intensities are not increasing
with the foreground intensities of the spots. Further the average intensity of the
lowest three concentrations are similar between dierent background and not back-
ground corrected methods. Therefore we will not use spots with a spike-in concen-
tration lower than 21:57 for further analysis. To specify the bias we t the following
linear model to the spike-in probes
log2 I = 0 + 1 log2C +  (5.2)
where I are the intensity values measured, C the spike-in concentrations and 
the error term. In the ideal case the slope would be equal to 1. Table 5.3 shows
the estimated slopes for the dierent normalization methods. There are only small
dierences between the methods with similar background treatment. Slopes are
 0:6 if no background correction was performed and  0:7 if background correction
was done. Hence background correction is benecial in terms of intensity bias,
especially in the low intensity range.
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Table 5.2: Estimated copy number (log2) per spike-in oligo for the spike-in data set.
oligo id A-1 A-2 A-3 A-4 A-5 . . . A-9 A-10
AF159801 27.58 26.58 25.58 24.58 23.58 . . . 19.58 18.58
opHsV04TC000049 26.58 25.58 24.58 23.58 22.58 . . . 18.58 27.58
opHsV04TC000044 25.58 24.58 23.58 22.58 21.58 . . . 27.58 26.58
opHsV04TC000045 24.58 23.58 22.58 21.58 20.58 . . . 26.58 25.58
ATU91966 23.58 22.58 21.58 20.58 19.58 . . . 25.58 24.58
opHsV04TC000002 22.58 21.58 20.58 19.58 18.58 . . . 24.58 23.58
opHsV04TC000001 21.58 20.58 19.58 18.58 27.58 . . . 23.58 22.58
AF168390 20.58 19.58 18.58 27.58 26.58 . . . 22.58 21.58
AF159803 19.58 18.58 27.58 26.58 25.58 . . . 21.58 20.58
X56062 18.58 27.58 26.58 25.58 24.58 . . . 20.58 19.58
opHsV04TC000004 27.58 26.58 25.58 24.58 23.58 . . . 19.58 18.58
opHsV04TC000005 26.58 25.58 24.58 23.58 22.58 . . . 18.58 27.58
AF191028 25.58 24.58 23.58 22.58 21.58 . . . 27.58 26.58
AF198054 24.58 23.58 22.58 21.58 20.58 . . . 26.58 25.58
opHsV04TC000009 23.58 22.58 21.58 20.58 19.58 . . . 25.58 24.58
opHsV04TC000008 22.58 21.58 20.58 19.58 18.58 . . . 24.58 23.58
AF247559 21.58 20.58 19.58 18.58 27.58 . . . 23.58 22.58
X58149 20.58 19.58 18.58 27.58 26.58 . . . 22.58 21.58
opHsV04TC000052 19.58 18.58 27.58 26.58 25.58 . . . 21.58 20.58
opHsV04TC000051 18.58 27.58 26.58 25.58 24.58 . . . 20.58 19.58
Besides a low intensity bias the conservation of fold changes between dierent
samples is essential for the comparison of dierent biological backgrounds. To ex-
amine the reproducibility of fold changes between dierent samples of our data set,
we calculated the absolute fold changes of the spike-in probes between all pairs of
samples and compared these observed values with the expected fold changes given
by the concentration dierences. Figure 5.2(b) shows the results for the dierent
normalization procedures. For all normalization methods, the observed fold changes
increase linearly with the expected fold changes. Background corrected methods
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seem to achieve slightly higher fold changes than methods without background cor-
rection. Similar to the analysis above we t the linear model
fcobs = 0 + 1fcexp +  (5.3)
where the observed fold change fcobs is a linear function of the expected fold change
fcexp. This model is similar to the one used in section 5.1.2. The ideal result would
be a slope of 1. The results are summarized in table 5.3. Slopes are around 0.6 when
no background correction was done and 0.68 if the data was background corrected.
There is a bias that lowers the observed fold changes. Removing this bias from the
probes by performing background correction improves conservation of fold changes.
5.2.3 Receiver operating characteristic (ROC) analysis
For any analysis that involves the comparison of microarrays it is essential to distin-
guish between true and random dierences between the microarrays. This is only
possible if the true dierences are stronger than such that occur by chance. We use
ROC curves to illustrate how well fold changes between spike-in probes of dierent
arrays can be separated from the biological background (non spike-in probes). For
a series of fold change thresholds ROC analysis compares the resulting true posi-
tives ratio (TPR) with the false positive ratio (FPR). A TPR is the fraction of fold
changes originating from spike-in probes that are bigger than a certain threshold.
In contrast the FPR is the fraction of fold changes originating from non spike-in
probes that are bigger than this threshold. Optimally there exists a threshold that
is smaller than all spike-in fold changes, but larger than all non spike-in fold changes.
In this case, the ROC curve climbs rapidly away from the origin (lower left hand
corner). A common application of microarray analysis is the comparison of dierent
groups of samples. Probe fold changes between these groups are averaged across all
samples within a group. Since our data set contains four groups of 10 samples, each
featuring the same spike-in Latin square table, we can mimic four spike-in replicates
by averaging across the groups. The resulting data set consists of 10 proles were
each probe intensity is an average across four samples. We calculated the absolute
fold changes between all 45 pairs of the 10 averaged proles and applied ROC analy-
sis. Figures 5.3(a) and 5.3(b) show the resulting ROC curves. The better the result
the closer a ROC curve gets to the upper right corner of the plot, which represents
a perfect separation between spike-in and non spike-in fold changes. The diagonal
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(a)
(b)
Figure 5.2: Boxplots illustrating sensitivity and fold change conservation. The dif-
ferent normalization methods are color coded as shown in the legend ('bg' indicates
background correction). (a) Observed spot intensities as a function of spike-in con-
centrations. Each box consists of the intensity values measured from the spike in
probes given a certain concentration across all arrays. (b) Observed fold changes
in comparison with expected fold changes between the spike-in probes of dierent
arrays. The absolute fold changes were calculated for each pair of arrays.
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line represents the case were the fractions of spike-in and non spike-in fold changes
that are above a given fold change threshold are equal. This situation is equivalent
to randomly picking probes that are above the threshold. How close the ROC curve
gets to the upper right corner can be quantied by measuring the area under the
curve (AUC).
All normalization methods are in the upper right triangle of the plots, meaning
that the separation between true and false positives is better than chance. Compar-
ing Figure 5.3(a) with 5.3(b) reveals that normalization procedures perform better
when no background correction was done. Likewise the AUC is bigger for meth-
ods without background correction, as shown in Table 5.3. Within a specic back-
ground correction mode all normalization procedures perform better than unnormal-
ized data except the vsn method. The dierences between the other normalization
methods are only marginal. The loess and loess-quantile method performs slightly
better than the quantile method.
5.2.4 Classication analysis
In this section we investigate, if the application of dierent normalization methods
aects the classication problems inherent in our data. There are three such prob-
lems, two involving 2-classes and one involving 4-classes. For the 2-class problems
we train classiers separating the activated from arrested cell samples for the Cal51
and T47D cell lines separately. In the 4-class problem we train a classier that
separates all classes of the 2-class problems at once. We used a nearest shrunken
centroid (NSC) classier implemented in the R-package PAMr (Tibshirani et al.,
2002) with default settings for all classication tasks. Each classier was evaluated
by 10-fold cross validation (CV). The CV-errors were averaged across 50 indepen-
dent CV runs for the 2-class problems and across 100 independent CV runs for the
4-class problem. The results are shown in Figures 5.3(c), 5.3(d) and 5.3(e).
For both 2-class problems we were able to train classiers with low CV errors
 0:05 (1 sample) with all normalization methods using between 100 and 1000 genes.
Only unnormalized data, with and without background correction, performed worse.
The 4-class problem is more complex. It could also be solved independent of the
normalization methods used. But more genes ( 1000) were needed to achieve a CV
error of  0:03. Again unnormalized data, with and without background correction,
performed worse (CV error: 0:09  4 samples). Table 5.3 summarizes the CV errors
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(a) (b)
(c) (d) (e)
Figure 5.3: (a,b) ROC analysis using fold changes between spike-in probes as posi-
tives and fold changes between non spike-in probes as negatives. (a) normalization
without background correction (b) normalization with background correction. (c-e)
PAMr 10-fold cross validation error averaged across 10 independent runs as a func-
tion of the number of genes used by the classier. (c) Cal51 activated vs. arrested
(d) T47D activated vs. arrested (e) 4-class problem: Cal51 & T47D activated vs.
arrested.
achieved by the dierent normalization methods. For all investigated classication
problems application of background correction had no inuence on the classier
performance.
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Table 5.3: Regression slope estimates for spike-in concentration vs. probe intensi-
ties (A) and expected vs. observed fold changes (B). ROC analysis: Area Under
the Curve was calculated using the trapezoidal rule. Classication: 10-fold cross
validation error for activated vs. arrested, Cal51 and T47D separate and combined.
slope estimates CV error
method A B ROC AUC Cal51 T47D combined
none 0.62 0.59 0.83 0.10 0.03 0.09
loess 0.62 0.59 0.84 0.05 0.00 0.02
quantile 0.61 0.59 0.84 0.05 0.00 0.02
loess-quantile 0.61 0.59 0.85 0.05 0.00 0.02
none-bg 0.71 0.66 0.80 0.10 0.00 0.09
loess-bg 0.71 0.68 0.82 0.05 0.00 0.02
quantile-bg 0.71 0.68 0.81 0.05 0.00 0.02
loess-quantile-bg 0.71 0.68 0.82 0.05 0.00 0.02
vsn 0.73 0.70 0.79 0.05 0.00 0.03
5.2.5 Dierential gene expression analysis
Dierential gene expression analysis will be one of the major applications of sin-
gle cell analysis. Using our data set we searched for genes that are dierentially
expressed between the activated and arrested samples within each cell line. We
employed the R package limma (Smyth, 2004) to perform the calculations.
The number of signicant dierentially expressed genes (Padj  0:05 ) ranged
from 47 to 91 genes for Cal51 depending on the normalization method and for
T47D from 330 to 641, respectively. The composition of genes sets was similar for
the dierent methods. Considering the overlap between all pairs of normalization
methods the fraction of genes included in both sets relative to the smaller set was
 90% for Cal51 and  74% for T47D.
To check if the biological dierence of our samples (activated vs. arrested) agrees
with the dierentially expressed genes, we performed gene ontology (GO) enrichment
analysis. This analysis checks whether sets of genes that belong to a specic biolog-
ical process, molecular function or cellular component are signicantly enriched in
the set of dierentially expressed genes. Here we use the sets of genes identied af-
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ter loess-quantile normalization with background correction. There were 76 probes
dierentially expressed in the Cal51 and 580 in the T47D cell line. Examples of
GO-terms most strongly enriched are shown in table 5.4.
Within the activated samples of the Cal51 cell line genes are up-regulated that
are connected with the absorption of metal ions. Metal ions play a key role in the
nutrition of cells and are essential for cell growth and cell division (Nelson, 1999).
GO-terms enriched in the T47D comparison suggest that the activated samples
are in the process of ribosome biogenesis. This process might be in control of cell
proliferation as it antagonizes cell cycle progression until the cell has grown to an
adequate size as described by Thomas (2000) and Bernstein et al. (2007). This
suggests that serum activation has a detectable impact on the transcriptome of
Cal51 and T47D cell lines.
5.3 Discussion
In this chapter we analyzed the capability of the Operon microarray platform in
terms of single cell gene expression proling. This platform is based on the 2-
channel cDNA technology. Hence in a standard setup one would measure a sample
on one channel and a corresponding control or common reference on the other chan-
nel. Since it is well known that dye specic eects may occur we performed a color
switch experiment investigating dye specic measurement dierences between sim-
ilar samples. We observed huge dierences between the measured probe intensities
of the two channels that were independent from the hybridized sample. Such behav-
ior can cause major problems in subsequent data analysis, as it disguises intensity
dierences reecting biological properties of the samples. Aware of this problem,
we investigated the conservation of fold changes between dierent samples within
the two channels. This is the most important property of a microarray technology
measuring gene expression, as expression dierences between arrays should reect
biological dierences between samples. Our results showed that only the Cy5 chan-
nel is able to correctly reproduce dened fold changes between biological samples.
As a consequence we used only the Cy5 channel of this platform in all following
applications.
We continued with comparing dierent normalization procedures in terms of bias
and their inuence on typical data analysis methods like classication and dier-
82
Table 5.4: GO-terms overrepresented in genes dierentially expressed between acti-
vated and arrested samples within the Cal51 or T47D cell line. Regulation is with
respect to the activated samples. Ontology abbr.: MF - molecular function, BP -
biological process, CP - cellular component.
GO-ID GO-term p-value regulation ontology
Cal51
GO:0046870 cadmium ion binding 5e-13 up MF
GO:0005507 copper ion binding 2e-07 up MF
GO:0008270 zinc ion binding 0.006 up MF
GO:0022614 membrane to membrane docking 3e-05 up BP
GO:0007159 leukocyte cell-cell adhesion 0.001 up BP
GO:0022406 membrane docking 0.002 up BP
T47D
GO:0003735 structural constituent of ribosome <2e-16 up MF
GO:0003723 RNA binding 2e-05 up MF
GO:0022890 inorganic cation transmembrane
transporter activity
3e-04 up MF
GO:0006412 translation 2e-12 up BP
GO:0022613 ribonucleoprotein complex biogene-
sis
2e-06 up BP
GO:0016072 rRNA metabolic process 3e-05 up BP
GO:0006355 regulation of transcription, DNA-
dependent
6e-04 down BP
GO:0022626 cytosolic ribosome 4e-16 up CP
GO:0030529 ribonucleoprotein complex 6e-13 up CP
GO:0033279 ribosomal subunit 3e-12 up CP
GO:0022627 cytosolic small ribosomal subunit 2e-11 up CP
ential gene expression based on a well dened spike-in dataset. We did not detect
large dierences between the dierent normalization methods. Bias, conservation of
fold changes between spike-in probes of dierent samples and classication accuracy
were comparable. Generally results on normalized data were better than when un-
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normalized data was used. The biggest inuence on performance has the application
of background correction. It notably reduces the intensity bias, especially in the low
intensity range, but increases the variance. This increase is disadvantageous and
can disguise real fold changes as it was shown in the ROC analysis.
Generally the noise present in single cell data is high, which might be due to addi-
tional amplication of sample mRNA. Unfortunately we can not make any statement
about this amplication step, since the spike-ins were made after the amplication
procedure. Only spike-ins before the amplication would have allowed us to asses
the inuence of the amplication procedure on the ratios of mRNA abundances
within a sample. It is technically impossible to reliable spike-in such a low amount
of sequence copy numbers that would match biological concentrations. Still spike-ins
after the amplication step are useful to assess bias and sensitivity of the platform.
A nal choice of the best normalization procedure is dicult since no method
had outstanding performance. We favor loess-quantile normalization which had a
consistently high performance. Background correction has pros and cons, but we
accept the increase of variance in change for bias reduction.
At the present state of technology we can reliably classify and predict single cell
samples of dierent biological backgrounds. Even complex multi class problems
can be solved correctly. Additionally dierential gene expression analysis identied
probes with signicant dierences in expression between the activated and arrested
cells. Gene set analysis of those genes conrmed the biological dierences intended
by serum stimulation. The Cal51 cell line responded with the absorption of metal
ions, which are essential for cell growth and division (Nelson, 1999). The T47D
cell line seems to be further progressed as regulated genes belong to the process of
ribosome biogenesis. Thomas (2000) and Bernstein et al. (2007) suggest that this
process is in control of the cell cycle as it antagonizes the cell cycle progression until
the cell has grown to an adequate size.
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Chapter 6
Analysis of transcriptome asymmetry
within mouse zygotes and embryonic
sister blastomeres
In the last chapter we examine on the prospects of gene expression analysis of single
cells using microarray technology. We compared arrested with serum activated cell
line samples and showed that typical applications of gene expression analysis, namely
classication and dierential gene expression analysis, are feasible. In this chapter
we focus on an application of single cell analysis. Embryogenesis is one of the most
fascinating processes in biology. A whole organism consisting of millions of cells,
dedicated to various tasks, originates from one single totipotent cell. This cell is the
zygote, which is formed by two highly dierentiated gamete cells, sperm and egg.
The gamete cells are not totipotent themselves, in the contrary they face assured
cell death if they do not combine. This change of cell fate, that occurs during
fertilization may be archetypical and promises insights into other changes of cellular
potency.
Until today the processes underlying cell fate changes are not fully understood.
However, it is known that cellular potency is sometimes regulated by controlling
the asymmetric distribution of mRNAs during cell division, such that each daughter
cell retrieves a distinct mixture of mRNAs that contribute to lineage commitment
(Macara and Mili, 2008). This mechanism enables stem cells to divide such that
one daughter keeps the stem cell properties, while the other is committed to fur-
ther dierentiation (Lin, 2008). Examples come from Drosophila neuroblasts and
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mammalian skin stratication and dierentiation (Chia et al. (2008), Lechler and
Fuchs (2005)). These observations imply that underlying principles of asymmetric
cell division are conserved between dierent species and tissues. Asymmetric local-
ization of cytoplasmic mRNAs has been shown to be a conserved strategy by which
cell polarity is regulated. However, its direct contribution to the formation of cell
pluripotency is poorly understood.
Non-uniform distribution of cytoplasmic mRNA during gametogenesis and em-
bryogenesis can be observed in dierent species. Dubowy and Macdonald (1998)
showed that at least 10% of the transcriptome in Drosophila oocytes is distributed
non-uniformly. This fraction increases to 71% in early embryos (Lécuyer et al., 2007).
In vertebrates like Xenopus laevis it has been shown that the synthesis of maternal
proteins is located by segmenting mRNAs (King (1995), Mowry and Cote (1999),
King et al. (2005), Holt and Bullock (2009)). For the formation of the animal and
vegetal poles in the oocyte this segmentation is of critical importance (Nieuwkoop,
1985). It involves the Balbiani body formation during maturation, which can be also
observed in mouse embryos (Pepling et al. (2007), Kloc et al. (2008)). This suggests
that mechanisms involving asymmetry have been conserved. Although asymmetric
mRNA distribution has been observed in dierent mammalian cell types it remains
unclear whether it is present in mammalian oocytes and early embryos (Mili et al.,
2008).
The answer to this question is essential for clarifying whether or not oocyte and/or
embryonic mRNA patterning inuence the establishment of cellular totipotence in
early mammalian development. So far related experiments deliver arguments for
both, positive and negative answers. On the one hand Torres-Padilla et al. (2007)
showed with 4-cell mouse embryos that methylation levels of the histone H3 correlate
with the fate of each blastomere lineage. Cells with low methylation levels contribute
more to the trophectoderm, while cells with high methylation levels contribute more
to the inner cell mass. On the other hand data of Kurotaki et al. (2007) suggests
that early embryonic lineages are not pre-determined maternally or in the earliest
phase of embryogenesis. However, it is certain that cellular totipotency is present in
mouse cell short after fertilization until at least the 8-cell embryo (Tarkowski (1959),
Kelly (1977)).
We address the question of asymmetric mRNA patterning by measuring tran-
scriptome distributions within mouse oocytes and pre-nuclear zygotes, and between
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sister blastomeres of single embryos after rst and second mitotic division. This
analysis was performed in cooperation with the laboratory of mammalian molec-
ular embryology of Dr. Perry from the RIKEN center for developmental biology
in Kobe, Japan, and the Klein lab from the department of pathology in Regens-
burg, Germany. The results of our joined work are published in the EMBO journal
(Vermilyea et al., 2011).
6.1 Data set
Collection and culture of mouse oocytes, zygotes and blastomeres from 2- and 3-
cell blastomeres and all necessary microsurgery was done by the lab of T. Perry.
Additional qPCR measurements for transcript quantication in single cells and cell
fragments to validate the microarray data were done there too. Microarray prepa-
ration, including PCR, sample labeling and array hybridization was done in the
lab of C. Klein. The gene expression data set consisted of 120 microarray samples
composed of 4 subsets of dierent sample types, namely 10 spindle-oocyte pairs,
16 polar body II (Pb2)-zygote couplets, 22 pairs of sister blastomeres derived from
2-cell embryos and 8 triplets of sister blastomeres derived from 3-cell embryos.
The 10 oocyte-spindle pairs were generated by microsurgical removal of the spin-
dle apparatus form unfertilized metaphase II oocytes. The spindle and remnant
samples were then subject to gene expression microarray analysis. This will answer
the question whether certain mRNAs are more associated with the spindle than
others.
Pb2-zygote couplets were harvested as soon as the Pb2 was generated by the
zygote after fertilization. Comparison of the transcriptomes may reveal specic
mRNAs that are removed from the zygote via the Pb2.
Sister blastomeres of 2- and 3-cell embryos were collected as soon as the 1st or 2nd
mitotic cleavage occurred. This data can be used to decide whether an asymmetric
mRNA distribution exist between sister blastomeres of a single embryo.
The whole data set was preprocessed by applying loess-quantile normalization
with background correction as described in chapter 5.
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6.2 Supervised analysis of spindle-oocyte and
Pb2-zygote couplets
We begin by performing supervised analysis on the spindle-oocyte and Pb2-zygote
samples, namely classication and dierential gene expression. Classication will
determine whether it is possible to distinguish spindle from oocyte and zygote from
Pb2 samples using a particular set of genes. The dierential gene expression analysis
will order the measured genes according to their dierence between spindle and
oocyte, and Pb2 and zygote samples and determine if the dierences are statistically
signicant.
6.2.1 Classication
Classication analysis was done using the nearest shrunken centroid method pro-
posed by Tibshirani et al. (2002). We employed the R implementation from the
PAMr package with default settings. For further details on this classication method
see section 2.1.1. The default implementation of the NSC classier does not take
the pairing of our data into account. In a standard unpaired 2-class setting, where
the classes are denoted A and B, a classier decides whether an unknown sample
belongs to class A or B. However, in the paired setting two samples are given at a
time. The classier now needs to decide which of the two samples belongs to class
A and which to class B. If one sample is assigned to class A or B the other one has
to be of the dierent class. We can use this additional knowledge to our advantage
by adopting the classication procedure to the paired setting. To do so, we will
not train the classier on the samples themselves, but on the dierences within the
pairs. As an example we will use the spindle-oocyte couplets. We randomly sort
the couplets into two groups of equal size, A and B. For each couplet of type A we
subtract the spindle prole from the oocyte prole transcript by transcript. In con-
trast, couplets of type B are reversely subtracted, oocyte prole from spindle prole
transcript by transcript. This procedure transforms the two proles of a couplet into
one dierence. This dierence is either of type A or B. The NSC classier is now
trained on these dierences. Given an unknown couplet we can calculate its within
dierence and predict whether the dierence was of type A or B, automatically
implying the sample types. Classication accuracy was assessed by 10-fold cross
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(a) (b)
Figure 6.1: Cross validation errors achieved by NSC classiers trained on the spindle-
oocyte and zygote-Pb2 couplets in a (a) paired and (b) unpaired setting.
validation. The classication results are shown in Figure 6.1(a). The spindle-oocyte
classier had a CV error of zero when using at least 10 genes. The CV error of
the Pb2-zygote classier was 0:0625. Both classiers had an increased performance
due to the adoption of the paired setting. In Figure 6.1(b) the CV errors for the
unpaired scenario are shown, which are higher than in the paired analysis.
The low CV errors suggest that the transcriptomes of spindles on oocytes and
zygotes and Pb2 are distinguishable. An explanation could be a programmed sorting
of mRNAs within oocytes, assembling certain mRNAs close to the spindle. Further
the zygote might eject certain mRNAs to the Pb2. We will now address the question
which genes are dierently expressed between spindle and oocytes, and Pb2 and
zygote.
6.2.2 Dierential gene expression analysis
Dierential gene expression analysis was done by employing the limma package
implemented in R. Limma allows direct specication of the paired setting in the
analysis design. Raw P values were adjusted for multiple testing as proposed by
Benjamini and Hochberg (1995). Two comparisons are of interest: (i) spindle vs.
oocyte and (ii) Pb2 vs. zygote.
We begin with spindle vs. oocyte. We identied 384 transcripts to be signicantly
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Figure 6.2: Ordered list comparisons: The observed overlap sizes between the top
ranking mRNAs from the lists of mRNAs (a) enriched in spindle and Pb2 or (b)
depleted in spindle and Pb2 are signicantly greater than the magnitudes of overlaps
expected for randomly selected mRNAs. Vertical orange bars indicate the spread of
overlap sizes that occur if transcripts are chosen at random from both lists.
dierentially expressed (Padj  0:05). 95 of those transcripts showed a higher and
289 a lower mRNA abundance in the spindle compared to the oocyte samples.
Microarray data was veried by the laboratory of T. Perry using quantitative PCR
(qPCR) analysis of 30 transcripts in independently isolated single spindle-oocyte
couplets. Abundance changes were in agreement between microarray and qPCR
data for 25 of 30 transcripts (83:3%).
Our comparison of Pb2 vs. zygotes determined 1069 transcripts to be dierently
expressed. Here 572 transcripts showed higher and 497 lower mRNA abundance
in Pb2 compared to zygote samples. Again the microarray data was conrmed by
qPCR experiments on independent Pb2-zygote couplets.
Given that the spindle and Pb2 samples are derived from the same intracellular
region, their transcriptomes should overlap. We tested this hypothesis by comparing
the list of dierentially partitioned transcripts. Both lists were ordered, so that the
transcript most strongly enriched in spindle or Pb2 is on the rst position and the
transcript most strongly enriched in the oocyte or zygote is on the last position.
Then we employed the OrderedList package of Lottaz et al. (2006) to test whether
the lists overlap more strongly than would have been expected by chance. Figure
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6.2 shows the results. Both, spindle and Pb2 enriched as well as depleted transcripts
show highly signicant overlaps. Compared with Pb2-zygote pairs, fewer transcripts
achieved signicant concentration changes in spindle-oocyte couplets. Nevertheless,
transcript rankings correlate strongly, even when including transcripts falling below
the signicance threshold.
6.3 Unsupervised analysis of sister blastomeres
In the previous section we described the identication of transcriptome dierences
within spindle-oocyte and Pb2-zygote pairs following a supervised strategy. Now we
focus on the sister blastomeres derived from 2- and 3-cell embryos. Since a spatial
transcript distribution was detected in oocytes and zygotes, it might be transmitted
to the early embryo such that sister blastomere products of the rst or second mitosis
inherit distinct transcriptomes. We begin the analysis with the sister blastomeres
derived from 2-cell embryos in sections 6.3.1 and 6.3.2 and advance to analysis of
3-cell embryos in section 6.3.3.
Considering the paired structure of the expression data one can rephrase the
problem of asymmetric mRNA distribution as follows: Is there a set of genes that
separates all pairs of sister blastomeres into two classes A and B, so that one sample
of each pair belongs to class A and the other one to class B. Compared to the
situation in the last section this problem is unsupervised, since it is not a priori
possible to assign a given cell to a cell type. However, in this scenario, if one of the
cells could be assigned to class A the other would have to be of class B, distinguishing
the situation from standard unsupervised learning problems. Note that we are only
interested in expression dierences within pairs of samples, not between samples. We
address this by centering the expression values of all transcripts around zero within
each pair of sister blastomeres. Let X the matrix of pair-centered expression values,
then
xi;j = xi;j   xi;j ; (6.1)
where i runs across all transcripts and j across all samples, and xi;j is the mean
expression of transcript i within the pair including sample j. Obviously within each
pair of sister blastomeres we have
xi;1 =  xi;2 ; (6.2)
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where 1 and 2 indicate the two samples within a pair and i runs through all tran-
scripts.
6.3.1 A clustering approach for analyzing asymmetry of mRNA
distributions
An approach to determine whether it is possible to group the sister blastomeres into
the desired classes is clustering. If a conserved asymmetric distribution of mRNAs
within each pair exists, a cluster algorithm should group the samples accordingly
such that the two samples of each pair are in dierent clusters. Here we use the
partitioning around medoids (PAM) cluster algorithm described in section 2.1.1.
In a rst attempt we perform global clustering involving all genes. The distance
between any two samples s and t is dened as
d(s; t) =
vuut pX
i=1
(xi;s   xi;t)2 ; (6.3)
where p is the number of transcripts. This is the Euclidean distance in p dimensional
space. We choose this distance measure, because it reects abundance dierences
of transcripts between dierent proles. We achieved a valid clustering, in that
each pair of sister blastomeres was separated. However, we do not expect that an
asymmetric mRNA distribution will aect the whole transcriptome. Therefore we
rank all transcripts according to their contribution to the global pairwise distance.
We dene the contribution of a transcript g as the sum of univariate distances
between any two samples s and t
c(g) =
nX
i=1
nX
j=1
xg;i   xg;j : (6.4)
The top 1000 transcripts have large pairwise distance sums. We try to cluster the
pairs of sister blastomeres using only those top scoring transcripts and see whether
they are correctly separated or not. We increase the number of transcripts used
from 10 to 1000 in steps of 10. The resulting clusters are shown in Figure 6.3(a).
Non of the retrieved clusterings matches the global clustering result. But, all clus-
terings separate the sister blastomeres so that the samples of one pair are in dierent
clusters. This result is puzzling, since we assumed that if there is an asymmetric
mRNA distribution it will separate the sister blastomeres in one specic way. We
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(a) (b) (c)
Figure 6.3: (a) Separation of 2-cell sister blastomeres by clustering using the top
10   1000 transcripts with maximal variance. The color bar on top indicates the
global clustering result involving all transcripts. (b) Heatmap of the top 100 most
variable transcripts. Yellow indicates high and blue low transcript abundance. The
color bar on top indicates the global cluster result involving all transcripts. (c)
2-dimensional example of paired data were expression values are centered around
zero for all genes. The data points represent paired samples, where the pairing is
indicated by similar symbols. Due to the centering each pair is mirrored by the
origin. Hence any line through the origin gives a trivial solution to separate the
pairs into two groups, such that each group holds one sample of each pair.
investigate the clusterings result further by looking directly at the expression values.
Figure 6.3(b) shows a heatmap of the top 100 distance contributing transcripts. The
expression values are mixed, even though the samples are arranged according to the
clustering. It is reasonable to assume that this observation is an artifact of the data
or analysis method.
Indeed it can be easily shown that the pairwise centering of the sister blastomeres
makes a correct clustering possible with any set of genes. Given a set of transcript
wise centered pairs in a p-dimensional Euclidean space, where each transcript denes
a dimension, all pairs can be separated by any plane that runs through the origin,
given that no sample is located directly on this plane. This can be seen if we assume
the plane to be dened by a vector ~v of unit length. The projections of the sample
vectors ~s and ~t of any pair of sister blastomeres onto the axis dened by ~v is given
by the scalar products ~s  ~v and ~t  ~v. This projections are always on dierent sides
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of the origin since
~s  ~v =  (~t  ~v) (6.5)
as
~s  ~v =
pX
i=1
x1;svi (6.6)
and
~t  ~v =
pX
i=1
 x1;svi (6.7)
given equation 6.2, where p is the number of transcripts used. Figure 6.3(c) illus-
trates this artifact in a 2-dimensional example.
To answer the question if asymmetric mRNA distribution it truly present or not
we need to overcome this artifact. This can be done by rening and extending the
clustering approach as described in the next section.
6.3.2 Measuring group separation of sister blastomeres de-
rived from 2-cell embryos by cluster quality
We improve the clustering approach in two ways: (i) We rene the transcript lter-
ing, so that only those genes are used for clustering that exhibit a stable and strong
separation of pairs. (ii) We introduce a resampling based signicance test deciding
whether a separation of sister blastomeres is articial or real.
In the last section we ltered transcripts due to their univariate pairwise distances
between samples. We improve this ltering by directly focussing on the separation of
pairs. Transcripts should have large abundance dierences between the two samples
within a pair. Further the abundance dierences of all pairs should have low variance
across the pairs to ensure equally strong separation. Abundance dierences were
calculated transcript wise for each pair of sister blastomeres by subtracting the two
expression values from each other. Since this dierence can be either positive or
negative we used the absolute values. To rank the genes according to separation
strength and variance we employed a moderated one sided t-test. The t-statistic of
each transcript is given as
tscore =
p
n
x  0
 + 0
; (6.8)
where
 =
vuut 1
n  1
nX
i=1
(~x  x)2 (6.9)
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is the empirical standard deviation and
x =
1
n
nX
i=1
~xi (6.10)
is the mean across all within pair dierences ~x of a transcript. The number of pairs
is denoted by n, and 0 is the value from which means x should dier, here 0 = 0.
The fudge factor 0 is a positive constant that is added to the standard deviation
of each transcript. It guards against large tscore values arising from transcripts with
low abundances but even lower variability. We set 0 equal to the median value
of standard deviations over all transcripts. High values of tscore are achieved by
transcripts with large within pair dierences that show low variations. Using the
ranking by tscores we discarded all but the top N separating transcripts. We continue
the analysis with the resulting truncated expression proles.
To decide whether a clustering resulting from the top N separating transcripts
is an artifact we compare its quality with a null-distribution of cluster qualities.
This null-distribution is generated by determining the quality of 10000 clusterings
obtained from independent sets of N randomly chosen transcripts. A clustering
is of high quality if the two resulting classes are well separated. We measure this
separation strength by calculating cluster silhouettes s as proposed by Rousseeuw
(1987). A cluster silhouette is a value between  1 and 1, that describes the relation
of distances between samples of dierent clusters and distances between samples of
the same cluster. Clusterings of high quality achieve values close to 1 and have high
between cluster and low within cluster distances. Values around zero indicate that no
cluster structure is present. Negative values arise from wrong clusterings. A detailed
description of cluster silhouettes can be found in section 2.1.3. The probability that
the silhouette stop of a clustering using the top N separating transcripts appeared
by chance is given by the fraction of silhouettes sr achieved by clustering using N
randomly selected transcripts that are bigger than stop.
Silhouettes achieved by clusterings using the top N separating transcripts in
comparison to their null-distribution are shown in Figure 6.4(a). The number of used
transcripts N was varied from 2 to 100 in steps of 1. The observed silhouettes did not
exceed those from random clusters. Inspection of the top 100 separating transcripts
reveal no structure as shown in Figure 6.4(d). We thus conclude that there is no
detectable dierence within the transcriptomes of sister blastomeres derived from
2-cell embryos. However, even though our approach was well-thought-out it might
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be that it is unsuited for this type of data. Hence we validate our approach using the
spindle-oocyte and Pb2-zygote pairs. For the analysis we leave the known classes
aside and check whether the resulting clustering generate the right assignments.
Within pair dierences were calculated and transcripts ranked as described above.
Likewise cluster silhouettes were calculated for the top N separating transcripts as
well as for 10000 random clusters. In both cases separation strengths exceed by-
chance expectations and conrmed spindle-oocyte and Pb2-zygote assignments as
shown in Figures 6.4(c) and 6.4(b). Only one Pb2-zygote pair was assigned wrong.
Further inspection of the top 100 separating transcripts show a clear cluster structure
(Figures 6.4(f) and 6.4(e)). This validates our approach and shows that the analysis
strategy has the power to expose hidden classes of transcriptomes. Consistent with
this analysis we were unable to classify 2-cell blastomeres by qPCR (Vermilyea et al.,
2011).
6.3.3 Detection of asymmetric mRNA distribution in sister
blastomeres derived from 3-cell embryos
Undetectable transcriptome segregation between sister blastomeres of 2-cell embryos
does not formally exclude the possibility that asymmetries occur in the second mi-
totic products. A spatial mRNA distribution may be inherited and conserved during
the rst mitotic division as illustrated by Figure 6.5. To evaluate this alternative
we analyzed transcript proles of sister blastomeres derived from 3-cell embryos.
Altogether 8 triplets blastomeres were available, measured by 24 individual proles.
We employ the same analysis approach as described above. However, the triplet
scenario yields constraints that need to be reected in the statistical analysis. Given
that during the rst mitotic division the transcriptome is distributed uniformly be-
tween parent and daughter cell, we further assume that the second mitotic division
generates asymmetric transcriptomes, then for some transcripts the mRNA abun-
dance of the remaining rst mitotic product is lower than one of the second mitotic
products and higher than that of the other one. That means, given a blastomere
triplet, where A is the remaining undivided rst mitotic product and B,  are the
two second mitotic products, each asymmetric distributed transcript can order the
triplet according to its abundance as , A, B or B, A, . Therefore we aim to
cluster the blastomere triplets into three classes (type A, B and ). Since transcript
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Figure 6.4: Cluster analysis of sister blastomeres derived from 2-cell embryos on the
left, spindle-oocyte pairs in the middle and Pb2-zygote pairs on the right. (a-c)
Silhouettes achieved by clusterings using the top N separating transcripts are indi-
cated by the red line. Grey background shading reects the distribution of matching
random silhouettes. Darker colors represent higher densities. (d-f) Heatmaps of top
100 separating transcripts, yellow indicates high and blue low mRNA abundance.
The two clusters are indicated by the color bar on top.
abundances can be on dierent levels we center each triplet around the remaining
rst mitotic product A, by subtracting A from B and  for each transcript. Let X
be the matrix of centered triplets, then
xi;j = xi;j   xi;A (6.11)
where i runs across all transcripts and j across all samples. xi;A is the matching
A-type sample of triplet including j. Hence all A-type proles have a constant
centered transcript abundance of zero. Likewise to the analysis above we rank
the transcripts according to their potential separation strength within the triplets.
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Figure 6.5: Asymmetric maternal transcriptome inheritance may persist through
the early zygote (ez) and not be detected until the rst (upper) or second mitotic
division. Polarity determinants marking the lineages are shown as red or blue.
Asymmetry detection (boxed) is possible after rst (upper) or second mitosis. Image
was taken from Vermilyea et al. (2011).
Instead of the t-test we use the Jonckheere-Terpstra test (Jonckheere, 1954), which
test for a monotone trend in terms of given classes. In the three class case the test
statistic is dened as
jtscore =
2X
i=1
3X
j=i+1
#(ci; cj) (6.12)
with
#(ci; cj) =
X
e2ci
X
f2cj
 (xt;e   xt;f ) (6.13)
and
 (v) =
8<:1 if v < 00 else (6.14)
where t is any transcript and c are the sample classes with c1 including samples of
type , c2 samples of type A and c3 samples of type B. Here we assume that for any
triplet the abundance value of type  is smaller than the abundance value of type
B. We ensure this by sorting the triplets. We continue with truncated proles using
only the top N separating transcripts. Clustering and calculation of silhouettes was
done similar to the paired scenario.
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Figure 6.6: Cluster analysis of sister blastomeres derived from 3-cell embryos. (a)
Silhouettes achieved by clusterings using the top N separating transcripts are indi-
cated by the red line. Grey background shading reects the distribution of matching
random silhouettes. Darker colors represent higher densities. (b) Heatmap of top
100 separating transcripts, yellow indicates high and blue low mRNA abundance.
The three clusters are indicated by the color bar (grey - A-, red - B- and blue -
-type).
The resulting silhouettes are shown in Figure 6.6(a). Again the separation strength
achieved by using the top N transcripts did not exceed random expectations. More-
over inspection of the top 100 separating transcripts shows no cluster structure. This
result was conrmed by qPCR analysis (Vermilyea et al., 2011). Thus, we found no
evidence for programmed transcriptome asymmetry between sister blastomeres of
3-cell embryos.
6.4 Discussion
In this chapter we reported on the problem of intracellular mRNA regionalization
by single subcellular transcriptome proling. Two question were addressed: (i) Does
non-uniform mRNA distribution exist in mammalian oocytes? (ii) Are transcrip-
tome asymmetries present in early embryonic development, that might result from
embryonic pre-patterning? We addressed the rst question by analyzing spindle-
oocyte and Pb2-zygote pairs. Investigation of sister blastomeres of 2- and 3-cell
blastomeres resolved the second question.
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From the bioinformatics perspective the comparison of spindle with oocyte sam-
ples as well as Pb2 with zygote samples can be accomplished with standard super-
vised approaches. Here we employed classication methods to showed that tran-
scriptome dierences within the spindle-oocyte and Pb2-zygote pairs exist. We
adopted the standard NSC classier to the paired setting by learning on within
pair abundance dierences instead of individual abundance values. This increased
the classier performance and allowed almost errorless separation of the sample
groups. Dierential gene expression analysis identied sets of transcripts that dier
signicantly within the pairs and ranked all transcripts according to their within
abundance dierence. Further analysis of those ranked lists showed that both spin-
dle/Pb2 up regulated and spindle/Pb2 down regulated transcripts overlap stronger
than expected by chance. This asymmetry might be a remnant from earlier oocyte
development, during which mRNA localization had a critical role. It is known that
spindle complexes are sites of targeted polysomal mRNA localization in diverse sys-
tems (Blower et al. (2007) Mili and Macara (2009)) and characteristically orchestrate
key elements of mouse oocyte maturation (Brunet and Verlhac, 2011). Spindle en-
richment of mRNAs might thus localize translation to target proteins during the
establishment of a fertilizable mII oocyte. Alternatively the strong overlap between
spindle and Pb2 enriched transcripts may suggest a unique tier of gene regulation
during the gamete-to-embryo transition.
The analysis of sister blastomeres derived from 2- and 3-cell embryos aimed to
detect sets of transcripts that consistently separate the pairs or triplets. This is
an unsupervised analysis scenario that we approached by clustering. However the
paired structure of samples derived from 2-cell embryos introduced an artifact that
generated consistent pair separation for any set of transcripts. To overcome this
artifact we developed a strategy that combined the gene ltering with analysis of
cluster separation to detect non articial separations. We did not detect conserved
transcriptome dierences within sister blastomeres of 2- or 3-cell embryos. However,
as a proof of principle we applied our approach to the spindle-oocyte and Pb2-zygote
pairs. We were able to identify the correct separation of pairs in both cases. Our
results are in line with the work of Hiiragi and Solter (2004), Motosugi et al. (2005),
Kurotaki et al. (2007) and Guo et al. (2010) who were unable to classify 2-cell
blastomeres according to reproducible dierences between them. Neither of the cells
makes a biased contribution to the inner cell mass or trophectoderm of the early
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embryo. Vermilyea et al. (2011) reason that if there is maternal or early embryonic
pattering in mammals, it is more likely to be mediated post-translationally. This
is in contrast to the targeted localization of oocyte derived mRNAs in Drosophila
and Xenopus, which result in developmentally critical transcriptome partitioning
between embryonic cells.
In summary, mice do not seem to utilize the developmental mechanism of non-
uniform mRNA distribution between sister blastomeres of the early embryo that is
highly conserved in other species, even though transcriptome asymmetries exist in
mouse oocytes.
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Part IV
Appendix
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Summary and Conclusions
Today microarray gene expression proling has become a routine high throughput
method in modern molecular biology laboratories. Gene expression data is used to
characterize and distinguish tissues, cells or tumors. However, the regulation and
interaction of genes is still not fully understood. In this context combination of gene
expression data with other per gene measurements like transcription factor binding
or response to a certain stimulus can improve the understanding of the underlying
regulatory mechanisms. Further, this approach enables us to categorize gene ex-
pression proles according to the additional information like the presence of a tran-
scription factor. This thesis aims to develop an algorithm that allows the integration
of clinical gene expression data with additional quantitative per gene measurements.
Another trend in the eld of gene expression proling is the analysis of single cells.
The employment of microarray technology for single cell analysis is rather new, but
applications range from the analysis of rare cell populations, like disseminated tumor
cells, to fertility medicine or embryogenesis, where single cells are of major impor-
tance. This thesis evaluates the prospects of single cell gene expression analysis
using the Operon GeneChip platform.
Genomic data integration This part of the thesis is dealing with integrating
gene expression data from clinical biopsies (clinical data) with additional quantita-
tive per gene measurements (guiding data). We begin with an introduction to the
eld of genomic data integration in the context of gene expression data in chapter
3. We criticize the sequential nature of existing analysis concepts. Genes are se-
lected either based on a coherent expression across the clinical or are high scoring
in terms of some statistic on the guiding data. Subsequently the gene set is applied
to the other data set. Hence the resulting signatures are either not inuenced by
the clinical, or they are not inuenced by the guiding data. In chapter 4 we propose
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a novel algorithm that selects genes based on both, the clinical and guiding data
in one single joint analysis. The algorithm is based on a kernel density estimation
approach and automatically weights both data sets against each other. It is named
guided clustering. A detailed description is given in section 4.2. We investigated
the performance of guided clustering in-depth by running a simulation study. The
results are compared with the sequential approaches in section 4.3. We observed
that guided clustering cannot outperform the sequential approaches with respect
to both, cluster tightness and enrichment of high scoring genes. But, it is the only
method able to perform good in both aspects simultaneously. In section 4.4 we show
two applications of guided clustering to real data. We integrate 220 lymphoma gene
expression proles with DNA binding anity of BCL6. This analysis identied a
set of genes whose summarized expression index is a highly signicant independent
predictor of survival. The associated hazard of this index is higher than other es-
tablished factors including ABC/GCB status, age and Ann Arbor staging. Gene set
analysis showed a signicant enrichment of genes involved in the Toll-like receptor
pathway. This connection between the Toll-like receptor pathway and BCL6 was
already described by Basso and Dalla-Favera (2010). To verify this nding we con-
ducted a LPS stimulation experiment on BL-2 cell lines, since LPS directly activated
the Toll-like receptors. Application of the guided clustering algorithm identied a
gene module whose summarized expression index is highly correlated with the BCL6
index, even though only the minority of genes overlap between both modules. This
further supports the hypothesis that BCL6 modulates the transcriptome of DLBCL
via Toll-like receptor signaling.
Within this thesis a novel data integration algorithm has been developed and
proven to work properly in the desired data setting. Guided clustering complements
existing standard approaches and even outperforms them. The application of guided
clustering to a lymphoma cancer data set discovered a novel independent factor for
survival and supported the hypothesis of Toll-like receptor signaling mediating BCL6
induced gene regulation.
Analysis of single cells In this part of the thesis we explore the prospects of
single cell gene microarray expression analysis. Chapter 5 evaluates the microarray
platform used for the analysis of single cells throughout this thesis. This evaluation
becomes necessary as measurement and analysis of single cells are more dicult
than normal tissue samples, that consist of several thousand cells. Investigation of
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the individual channels available on the Operon platform in section 5.1.1 and 5.1.2
showed that only the red channel is suitable for single cell analysis. Subsequently
we compared the performance of several normalization methods in section 5.2. We
designed a spike-in data set to asses the inuence of dierent normalization pro-
cedures on the gene expression data in terms of sensitivity, stability, classiability
and detection of dierential gene expression. We did not detect signicant dier-
ences between the dierent normalization methods, but normalization is benecial
compared to unnormalized data. Our analysis showed that standard applications of
gene expression data like classication and dierential gene expression analysis are
possible with single cell data.
To summarize, gene expression measurement of single cells is more dicult and the
resulting data is more noisy than those of usual tissue samples. Nevertheless anal-
ysis is possible, but has to be interpreted more carefully.
Encouraged by these results we applied our single cell gene expression platform
to a data set from developmental biology. This analysis is described in chapter
6 and investigates the two questions: (i) How is cellular pluripotency established
within the zygote? (ii) Is there an asymmetric mRNA distribution present in the
early mammalian development, like it is observed in other species like Drosophila or
Xenopus? We investigate the rst question in section 6.2 by analyzing spindle-oocyte
and Pb2-zygote couplets. We show that there are conserved dierences within the
transcriptomes of spindle-oocyte and Pb2-zygote couplets. This was achieved by
adopting the standard NSC classier to the paired setting of the data. Further we
detected transcripts enriched or depleted in the spindle and Pb2 and observed that
overlaps between these sets of transcripts were signicantly larger than expected by
chance. It is possible that the spindle is utilized to eject specic mRNAs from the
zygote via the Pb2. To answer the second question we analyze pairs and triplets
of expression proles derived from 2- or 3-cell sister blastomeres. In section 6.3 we
develop a novel analysis strategy to decide whether a conserved asymmetric mRNA
distribution exist within the pairs and triplets of sister blastomeres. We do not ob-
serve any conserved mRNA asymmetries. As a proof of principle we show that our
approach is able to detect mRNA asymmetries within the Pb2-zygote or spindle-
oocyte pairs. This supports our result that no asymmetric mRNA distributions are
present within 2- or 3- cell sister blastomeres.
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In summary, transcriptomic prepatterning during the rst two mitotic divisions is
either to subtle or not-existent. Hence, if there exists maternal prepatterning it
is more likely to be mediated post translationally. However, transcriptomic dier-
ences were identied between spindle and oocyte as well as between Pb2 and zygote
proles. In this context the spindle might be utilized by the cell to eject specic
mRNAs from the Pb2. Further analysis of the genes dierently expressed between
Pb2 and zygote might help do develop RNA-induced pluripotent stem cells. Addi-
tionally those genes might provide markers that can be used judge the viability of
and embryo. This would be a valuable tool in human assisted reproduction as it
allows the selection of single embryos.
Supplement
6.5 LPS sample preparation
BL2 cells were cultivated as described recently by Vockerodt et al. (2001). Cells
were incubated with 1g/ml LPS (Lipopolysaccharide from E. coli 055:B5, Sigma)
for 6hrs. Cells were harvested, washed with PBS containing 1mM Sodium ortho-
vanadate (Sigma) as described by Holtick et al. (2005). RNA was isolated using
the RNeasy Plus Mini Kit (Qiagen). For whole genome microarrays RNA was la-
belled for microarray hybridization using Aymetrix GeneChipTM IVT Labelling
Kit (Aymetrix). Fragmentation and hybridization of labelled anti sense RNA
on Human Genome U133Plus2.0TMarrays (Aymetrix) was performed according to
manufacturer's recommendations.
All lab work was performed by the lab of D. Kube from the university clinic for
hematology of Göttingen.
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6.6 Additional tables
Table 6.1: List of genes that are members of the BCL6-index2 module.
Accession Number Entrez Id Symbol Description
NM_139276 6774 STAT3 signal transducer and activator of transcription 3 (acute-phase re-
sponse factor)
NM_030938 81671 TMEM49 TMEM49 transmembrane protein 49
NM_002956 6249 CLIP1 CAP-GLY domain containing linker protein 1
NM_004049 597 BCL2A1 BCL2-related protein A1
NM_002110 3055 HCK hemopoietic cell kinase
NM_000880 3574 IL7 interleukin 7
NM_006399 10538 BATF basic leucine zipper transcription factor, ATF-like
NM_003929 8934 RAB7L1 RAB7, member RAS oncogene family-like 1
NM_016545 51278 IER5 immediate early response 5
NM_000594 7124 TNF tumor necrosis factor
NM_006465 10620 ARID3B AT rich interactive domain 3B (BRIGHT-like)
NM_007237 11262 SP140 SP140 nuclear body protein
NM_000560 963 CD53 CD53 molecule
NM_001558 3587 IL10RA interleukin 10 receptor, alpha
D29642 9938 ARHGAP25 Rho GTPase activating protein 25
NM_181078 50615 IL21R interleukin 21 receptor
NM_005204 1326 MAP3K8 mitogen-activated protein kinase kinase kinase 8
NM_001759 894 CCND2 cyclin D2
NM_018639 55884 WSB2 WD repeat and SOCS box-containing 2
NM_021105 5359 PLSCR1 phospholipid scramblase 1
NM_015149 23179 RGL1 ral guanine nucleotide dissociation stimulator-like 1
NM_002356 4082 MARCKS myristoylated alanine-rich protein kinase C substrate
NM_002114 3096 HIVEP1 human immunodeciency virus type I enhancer binding protein 1
NM_014372 26994 RNF11 ring nger protein 11
NM_000391 1200 TPP1 tripeptidyl peptidase I
NM_138444 115207 KCTD12 potassium channel tetramerisation domain containing 12
NM_000043 355 FAS Fas (TNF receptor superfamily, member 6)
NM_007318 5663 PSEN1 presenilin 1
NM_016546 51279 C1RL complement component 1, r subcomponent-like
NM_015364 23643 LY96 lymphocyte antigen 96
NM_002727 5552 SRGN serglycin
NM_001610 53 ACP2 acid phosphatase 2, lysosomal
NM_000201 3383 ICAM1 intercellular adhesion molecule 1
NM_000211 3689 ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
NM_005561 3916 LAMP1 lysosomal-associated membrane protein 1
NM_003461 7791 ZYX zyxin
NM_005627 6446 SGK1 serum/glucocorticoid regulated kinase 1
NM_000593 6890 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
NM_019034 54509 RHOF ras homolog gene family, member F (in lopodia)
NM_005658 7185 TRAF1 TNF receptor-associated factor 1
NM_002229 3726 JUNB jun B proto-oncogene
NM_000595 4049 LTA lymphotoxin alpha (TNF superfamily, member 1)
NM_005574 4005 LMO2 LIM domain only 2 (rhombotin-like 1)
NM_001165 330 BIRC3 baculoviral IAP repeat-containing 3
NM_004125 NA NA NA
NM_007315 6772 STAT1 signal transducer and activator of transcription 1, 91kDa
NM_022168 64135 IFIH1 interferon induced with helicase C domain 1
NM_000434 4758 NEU1 sialidase 1 (lysosomal sialidase)
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NM_016582 51296 SLC15A3 solute carrier family 15, member 3
NM_014314 23586 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
NM_019027 54502 RBM47 RNA binding motif protein 47
NM_000878 3560 IL2RB interleukin 2 receptor, beta
NM_018295 55281 TMEM140 transmembrane protein 140
NM_004454 2119 ETV5 ets variant 5
NM_003768 8682 PEA15 phosphoprotein enriched in astrocytes 15
NM_003263 7096 TLR1 toll-like receptor 1
NM_003332 7305 TYROBP TYRO protein tyrosine kinase binding protein
NM_007161 7940 LST1 leukocyte specic transcript 1
NM_006407 10550 ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5
NM_006317 10409 BASP1 brain abundant, membrane attached signal protein 1
NM_000399 1959 EGR2 early growth response 2
NM_001665 391 RHOG ras homolog gene family, member G (rho G)
NM_016061 51646 YPEL5 yippee-like 5 (Drosophila)
NM_001310 1389 CREBL2 cAMP responsive element binding protein-like 2
NM_007229 11252 PACSIN2 protein kinase C and casein kinase substrate in neurons 2
NM_032895 84981 C17orf91 chromosome 17 open reading frame 91
NM_002118 3109 HLA-DMB major histocompatibility complex, class II, DM beta
NM_199418 5547 PRCP prolylcarboxypeptidase (angiotensinase C)
NM_002468 4615 MYD88 myeloid dierentiation primary response gene (88)
NM_000958 5734 PTGER4 prostaglandin E receptor 4 (subtype EP4)
NM_017791 55640 FLVCR2 feline leukemia virus subgroup C cellular receptor family, member 2
NM_030762 79365 BHLHE41 basic helix-loop-helix family, member e41
NM_021259 58986 TMEM8A transmembrane protein 8A
NM_053056 595 CCND1 cyclin D1
NM_006148 3927 LASP1 LIM and SH3 protein 1
NM_152862 10109 ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa
NM_000952 5724 PTAFR platelet-activating factor receptor
NM_002406 4245 MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase
NM_001084 8985 PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
NM_000332 6310 ATXN1 ataxin 1
NM_031858 4077 NBR1 neighbor of BRCA1 gene 1
NM_007278 11337 GABARAP GABA(A) receptor-associated protein
NM_002117 3107 HLA-C major histocompatibility complex, class I, C
NM_004383 1445 CSK c-src tyrosine kinase
NM_018668 26276 VPS33B vacuolar protein sorting 33 homolog B (yeast)
NM_004184 7453 WARS tryptophanyl-tRNA synthetase
NM_030796 81552 VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1
NM_021009 7316 UBC ubiquitin C
NM_002984 6351 CCL4 chemokine (C-C motif) ligand 4
NM_018247 55754 TMEM30A transmembrane protein 30A
NM_002349 4065 LY75 lymphocyte antigen 75
NM_020755 57515 SERINC1 serine incorporator 1
NM_003900 8878 SQSTM1 sequestosome 1
NM_005669 7905 REEP5 receptor accessory protein 5
L78132 3964 LGALS8 lectin, galactoside-binding, soluble, 8
NM_006813 10957 PNRC1 proline-rich nuclear receptor coactivator 1
NM_030797 81553 FAM49A family with sequence similarity 49, member A
NM_003820 8764 TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus
entry mediator)
NM_001859 1317 SLC31A1 solute carrier family 31 (copper transporters), member 1
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NM_001995 2180 ACSL1 acyl-CoA synthetase long-chain family member 1
NM_001500 2762 GMDS GDP-mannose 4,6-dehydratase
NM_006403 4739 NEDD9 neural precursor cell expressed, developmentally down-regulated 9
NM_000206 3561 IL2RG interleukin 2 receptor, gamma
NM_080593 85236 HIST1H2BK histone cluster 1, H2bk
NM_002355 4074 M6PR mannose-6-phosphate receptor (cation dependent)
NM_022371 64222 TOR3A torsin family 3, member A
NM_005717 10092 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa
NM_014313 23585 TMEM50A transmembrane protein 50A
NM_198892 55589 BMP2K BMP2 inducible kinase
NM_001659 377 ARF3 ADP-ribosylation factor 3
NM_002199 3660 IRF2 interferon regulatory factor 2
NM_000271 4864 NPC1 Niemann-Pick disease, type C1
NM_006827 10972 TMED10 transmembrane emp24-like tracking protein 10 (yeast)
NM_002983 NA NA NA
NM_003272 7107 GPR137B G protein-coupled receptor 137B
NM_024602 79654 HECTD3 HECT domain containing 3
NM_003407 7538 ZFP36 zinc nger protein 36, C3H type, homolog (mouse)
NM_003299 7184 HSP90B1 heat shock protein 90kDa beta (Grp94), member 1
NM_004419 1847 DUSP5 dual specicity phosphatase 5
NM_000572 3586 IL10 interleukin 10
NM_018320 55298 RNF121 ring nger protein 121
NM_006875 11040 PIM2 pim-2 oncogene
NM_145804 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2
NM_004418 1844 DUSP2 dual specicity phosphatase 2
NM_002037 2534 FYN FYN oncogene related to SRC, FGR, YES
NM_016323 51191 HERC5 hect domain and RLD 5
NM_020739 9236 CCPG1 cell cycle progression 1
NM_022130 64083 GOLPH3 golgi phosphoprotein 3 (coat-protein)
NM_002872 5880 RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP
binding protein Rac2)
NM_005668 7903 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4
NM_004811 9404 LPXN leupaxin
NM_006889 942 CD86 CD86 molecule
NM_002209 3683 ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte function-
associated antigen 1; alpha polypeptide)
NM_015999 51094 ADIPOR1 adiponectin receptor 1
NM_007207 11221 DUSP10 dual specicity phosphatase 10
NM_000520 3073 HEXA hexosaminidase A (alpha polypeptide)
NM_032582 84669 USP32 ubiquitin specic peptidase 32
NM_014153 29066 ZC3H7A zinc nger CCCH-type containing 7A
NM_004045 475 ATOX1 ATX1 antioxidant protein 1 homolog (yeast)
NM_016133 51141 INSIG2 insulin induced gene 2
NM_020374 57102 C12orf4 chromosome 12 open reading frame 4
NM_006785 10892 MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1
NM_001154 308 ANXA5 annexin A5
NM_001946 1848 DUSP6 dual specicity phosphatase 6
NM_005125 9973 CCS copper chaperone for superoxide dismutase
NM_014705 9732 DOCK4 dedicator of cytokinesis 4
NM_002648 5292 PIM1 pim-1 oncogene
NM_152244 29916 SNX11 sorting nexin 11
NM_016951 51192 CKLF chemokine-like factor
NM_004691 9114 ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1
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NM_000127 2131 EXT1 exostosin 1
NM_002228 3725 JUN jun proto-oncogene
NM_024508 79413 ZBED2 zinc nger, BED-type containing 2
NM_025079 80149 ZC3H12A zinc nger CCCH-type containing 12A
NM_006748 6503 SLA Src-like-adaptor
NM_006437 143 PARP4 poly (ADP-ribose) polymerase family, member 4
NM_012249 23433 RHOQ ras homolog gene family, member Q
NM_006537 9960 USP3 ubiquitin specic peptidase 3
NM_007126 7415 VCP valosin-containing protein
NM_003896 8869 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5
NM_205847 29926 GMPPA GDP-mannose pyrophosphorylase A
NM_005923 4217 MAP3K5 mitogen-activated protein kinase kinase kinase 5
NM_018009 55080 TAPBPL TAP binding protein-like
NM_004833 9447 AIM2 absent in melanoma 2
NM_001693 526 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2
NM_001382 1798 DPAGT1 dolichyl-phosphate (UDP-N-acetylglucosamine) N-
acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase)
NM_017699 54847 SIDT1 SID1 transmembrane family, member 1
NM_020657 57343 ZNF304 zinc nger protein 304
NM_015346 23503 ZFYVE26 zinc nger, FYVE domain containing 26
NM_003113 6672 SP100 SP100 nuclear antigen
NM_003945 8992 ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1
NM_002087 2896 GRN granulin
NM_006016 8763 CD164 CD164 molecule, sialomucin
NM_014923 22862 FNDC3A bronectin type III domain containing 3A
NM_006384 10519 CIB1 calcium and integrin binding 1 (calmyrin)
NM_015388 25844 YIPF3 Yip1 domain family, member 3
NM_006923 6388 SDF2 stromal cell-derived factor 2
NM_014182 29095 ORMDL2 ORM1-like 2 (S. cerevisiae)
NM_006313 9958 USP15 ubiquitin specic peptidase 15
NM_004161 5861 RAB1A RAB1A, member RAS oncogene family
NM_006405 10548 TM9SF1 transmembrane 9 superfamily member 1
NM_007348 22926 ATF6 activating transcription factor 6
NM_004079 1520 CTSS cathepsin S
NM_000259 4644 MYO5A myosin VA (heavy chain 12, myoxin)
NM_017445 NA NA NA
NM_000633 596 BCL2 B-cell CLL/lymphoma 2
NM_006432 10577 NPC2 Niemann-Pick disease, type C2
NM_006811 10955 SERINC3 serine incorporator 3
NM_003199 6925 TCF4 transcription factor 4
NM_014350 25816 TNFAIP8 tumor necrosis factor, alpha-induced protein 8
NM_003190 6892 TAPBP TAP binding protein (tapasin)
NM_002298 3936 LCP1 lymphocyte cytosolic protein 1 (L-plastin)
AB014574 23307 FKBP15 FK506 binding protein 15, 133kDa
NM_015994 51382 ATP6V1D ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D
NM_006284 6881 TAF10 TAF10 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 30kDa
NM_005345 3303 HSPA1A heat shock 70kDa protein 1A
NM_004288 9595 CYTIP cytohesin 1 interacting protein
NM_005067 6478 SIAH2 seven in absentia homolog 2 (Drosophila)
NM_001777 961 CD47 CD47 molecule
NM_005160 157 ADRBK2 adrenergic, beta, receptor kinase 2
NM_003879 8837 CFLAR CASP8 and FADD-like apoptosis regulator
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NM_032263 84223 IQCG IQ motif containing G
NM_003764 8676 STX11 syntaxin 11
NM_018447 55831 TMEM111 transmembrane protein 111
NM_001375 1777 DNASE2 deoxyribonuclease II, lysosomal
NM_001295 1230 CCR1 chemokine (C-C motif) receptor 1
NM_005506 950 SCARB2 scavenger receptor class B, member 2
NM_005761 10154 PLXNC1 plexin C1
NM_004430 1960 EGR3 early growth response 3
NM_006457 10611 PDLIM5 PDZ and LIM domain 5
NM_004800 9375 TM9SF2 transmembrane 9 superfamily member 2
NM_020532 57142 RTN4 reticulon 4
NM_012428 27020 NPTN neuroplastin
NM_006066 10327 AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase)
NM_203463 253782 LASS6 LAG1 homolog, ceramide synthase 6
NM_004604 6810 STX4 syntaxin 4
NM_015497 25963 TMEM87A transmembrane protein 87A
BC002646 3725 JUN jun proto-oncogene
NM_005433 7525 YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
NM_004075 1407 CRY1 cryptochrome 1 (photolyase-like)
NM_134421 3241 HPCAL1 hippocalcin-like 1
NM_005514 3106 HLA-B major histocompatibility complex, class I, B
NM_004339 754 PTTG1IP pituitary tumor-transforming 1 interacting protein
NM_006736 3300 DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2
NM_057158 1846 DUSP4 dual specicity phosphatase 4
NM_018179 55729 ATF7IP activating transcription factor 7 interacting protein
NM_005335 3059 HCLS1 hematopoietic cell-specic Lyn substrate 1
NM_002502 4791 NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2
(p49/p100)
NM_003033 6482 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1
NM_005620 6282 S100A11 S100 calcium binding protein A11
NM_000876 3482 IGF2R insulin-like growth factor 2 receptor
NM_019045 54521 WDR44 WD repeat domain 44
NM_033535 26234 FBXL5 F-box and leucine-rich repeat protein 5
NM_002064 2745 GLRX glutaredoxin (thioltransferase)
NM_000153 2581 GALC galactosylceramidase
NM_030790 81533 ITFG1 integrin alpha FG-GAP repeat containing 1
NM_006368 10488 CREB3 cAMP responsive element binding protein 3
NM_030666 1992 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1
NM_006184 4924 NUCB1 nucleobindin 1
NM_003290 7171 TPM4 tropomyosin 4
NM_015303 23355 VPS8 vacuolar protein sorting 8 homolog (S. cerevisiae)
NM_001334 1519 CTSO cathepsin O
NM_002868 5869 RAB5B RAB5B, member RAS oncogene family
NM_001690 523 ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A
NM_007001 11046 SLC35D2 solute carrier family 35, member D2
NM_003009 6415 SEPW1 selenoprotein W, 1
NM_023079 65264 UBE2Z ubiquitin-conjugating enzyme E2Z
NM_198183 9246 UBE2L6 ubiquitin-conjugating enzyme E2L 6
NM_017631 55601 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
NM_002194 3628 INPP1 inositol polyphosphate-1-phosphatase
NM_021960 4170 MCL1 myeloid cell leukemia sequence 1 (BCL2-related)
NM_004926 677 ZFP36L1 zinc nger protein 36, C3H type-like 1
NM_006624 10771 ZMYND11 zinc nger, MYND domain containing 11
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NM_015602 26092 TOR1AIP1 torsin A interacting protein 1
NM_015368 24145 PANX1 pannexin 1
NM_017582 55585 UBE2Q1 ubiquitin-conjugating enzyme E2Q family member 1
NM_014301 23479 ISCU iron-sulfur cluster scaold homolog (E. coli)
NM_004972 3717 JAK2 Janus kinase 2
NM_022750 64761 PARP12 poly (ADP-ribose) polymerase family, member 12
NM_006714 10924 SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A
X56841 3133 HLA-E major histocompatibility complex, class I, E
NM_022821 64834 ELOVL1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3,
yeast)-like 1
D84454 7355 SLC35A2 solute carrier family 35 (UDP-galactose transporter), member A2
NM_012248 22928 SEPHS2 selenophosphate synthetase 2
NM_020199 56951 C5orf15 chromosome 5 open reading frame 15
NM_004637 7879 RAB7A RAB7A, member RAS oncogene family
NM_004688 9111 NMI N-myc (and STAT) interactor
NM_005533 3430 IFI35 interferon-induced protein 35
NM_000161 2643 GCH1 GTP cyclohydrolase 1
NM_002076 2799 GNS glucosamine (N-acetyl)-6-sulfatase
NM_001822 1123 CHN1 chimerin (chimaerin) 1
NM_000081 1130 LYST lysosomal tracking regulator
NM_015040 200576 PIKFYVE phosphoinositide kinase, FYVE nger containing
NM_199193 9577 BRE brain and reproductive organ-expressed (TNFRSF1A modulator)
NM_138720 3017 HIST1H2BD histone cluster 1, H2bd
NM_014701 9728 SECISBP2L SECIS binding protein 2-like
NM_004034 310 ANXA7 annexin A7
NM_004566 5209 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
NM_144977 163486 DENND1B DENN/MADD domain containing 1B
NM_005981 6302 TSPAN31 tetraspanin 31
NM_152866 931 MS4A1 membrane-spanning 4-domains, subfamily A, member 1
NM_014713 9741 LAPTM4A lysosomal protein transmembrane 4 alpha
NM_014741 9776 ATG13 ATG13 autophagy related 13 homolog (S. cerevisiae)
NM_006472 10628 TXNIP thioredoxin interacting protein
NM_004951 1880 GPR183 G protein-coupled receptor 183
NM_005730 10106 CTDSP2 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide
A) small phosphatase 2
NM_017740 55625 ZDHHC7 zinc nger, DHHC-type containing 7
NM_020119 56829 ZC3HAV1 zinc nger CCCH-type, antiviral 1
NM_006079 10370 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2
NM_025076 80146 UXS1 UDP-glucuronate decarboxylase 1
NM_017583 54765 TRIM44 tripartite motif-containing 44
NM_021729 55823 VPS11 vacuolar protein sorting 11 homolog (S. cerevisiae)
NM_005449 9214 FAIM3 Fas apoptotic inhibitory molecule 3
NM_015292 23344 ESYT1 extended synaptotagmin-like protein 1
NM_003331 7297 TYK2 tyrosine kinase 2
NM_016248 11215 AKAP11 A kinase (PRKA) anchor protein 11
NM_007131 7626 ZNF75D zinc nger protein 75D
AF055376 4094 MAF v-maf musculoaponeurotic brosarcoma oncogene homolog (avian)
NM_005713 10087 COL4A3BP collagen, type IV, alpha 3 (Goodpasture antigen) binding protein
NM_078476 11120 BTN2A1 butyrophilin, subfamily 2, member A1
NM_145725 7187 TRAF3 TNF receptor-associated factor 3
NM_002618 5194 PEX13 peroxisomal biogenesis factor 13
NM_199072 29969 MDFIC MyoD family inhibitor domain containing
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NM_017567 55577 NAGK N-acetylglucosamine kinase
NM_015568 26051 PPP1R16B protein phosphatase 1, regulatory (inhibitor) subunit 16B
NM_021175 57817 HAMP hepcidin antimicrobial peptide
NM_002827 5770 PTPN1 protein tyrosine phosphatase, non-receptor type 1
NM_001001481 55284 UBE2W ubiquitin-conjugating enzyme E2W (putative)
NM_016053 51019 CCDC53 coiled-coil domain containing 53
NM_032283 84243 ZDHHC18 zinc nger, DHHC-type containing 18
NM_013314 29760 BLNK B-cell linker
NM_001779 965 CD58 CD58 molecule
NM_004310 399 RHOH ras homolog gene family, member H
NM_019111 3122 HLA-DRA major histocompatibility complex, class II, DR alpha
NM_014548 29767 TMOD2 tropomodulin 2 (neuronal)
NM_032227 84187 TMEM164 transmembrane protein 164
NM_005475 10019 SH2B3 SH2B adaptor protein 3
NM_004290 9604 RNF14 ring nger protein 14
NM_177538 57404 CYP20A1 cytochrome P450, family 20, subfamily A, polypeptide 1
NM_000484 351 APP amyloid beta (A4) precursor protein
NM_000183 3032 HADHB hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-
CoA hydratase (trifunctional protein), beta subunit
NM_004855 9488 PIGB phosphatidylinositol glycan anchor biosynthesis, class B
NM_014506 27348 TOR1B torsin family 1, member B (torsin B)
NM_033339 840 CASP7 caspase 7, apoptosis-related cysteine peptidase
NM_003877 8835 SOCS2 suppressor of cytokine signaling 2
NM_006277 50618 ITSN2 intersectin 2
NM_003144 6745 SSR1 signal sequence receptor, alpha
NM_006633 10788 IQGAP2 IQ motif containing GTPase activating protein 2
NM_004635 7867 MAPKAPK3 mitogen-activated protein kinase-activated protein kinase 3
NM_002250 3783 KCNN4 potassium intermediate/small conductance calcium-activated chan-
nel, subfamily N, member 4
NM_003516 NA NA NA
NM_003512 8334 HIST1H2AC histone cluster 1, H2ac
NM_005180 648 BMI1 BMI1 polycomb ring nger oncogene
NM_003930 8935 SKAP2 src kinase associated phosphoprotein 2
NM_014937 22876 INPP5F inositol polyphosphate-5-phosphatase F
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NM_016623 51571 FAM49B family with sequence similarity 49, member B
NM_004504 3267 AGFG1 ArfGAP with FG repeats 1
NM_000945 5534 PPP3R1 protein phosphatase 3, regulatory subunit B, alpha
NM_006136 830 CAPZA2 capping protein (actin lament) muscle Z-line, alpha 2
NM_014044 25972 UNC50 unc-50 homolog (C. elegans)
NM_004034 310 ANXA7 annexin A7
NM_012428 27020 NPTN neuroplastin
NM_003816 8754 ADAM9 ADAM metallopeptidase domain 9
NM_003101 6646 SOAT1 sterol O-acyltransferase 1
NM_003851 8804 CREG1 cellular repressor of E1A-stimulated genes 1
NM_014028 28962 OSTM1 osteopetrosis associated transmembrane protein 1
NM_000310 5538 PPT1 palmitoyl-protein thioesterase 1
NM_003338 7321 UBE2D1 ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast)
NM_007246 11275 KLHL2 kelch-like 2, Mayven (Drosophila)
NM_016078 51030 FAM18B1 family with sequence similarity 18, member B1
NM_006016 8763 CD164 CD164 molecule, sialomucin
NM_002408 4247 MGAT2 mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase
NM_002485 4683 NBN nibrin
NM_003968 9039 UBA3 ubiquitin-like modier activating enzyme 3
NM_033339 840 CASP7 caspase 7, apoptosis-related cysteine peptidase
AJ131244 10802 SEC24A SEC24 family, member A (S. cerevisiae)
NM_024920 79982 DNAJB14 DnaJ (Hsp40) homolog, subfamily B, member 14
NM_001920 NA NA NA
NM_003144 6745 SSR1 signal sequence receptor, alpha
NM_030939 81688 C6orf62 chromosome 6 open reading frame 62
NM_181836 51014 TMED7 transmembrane emp24 protein transport domain containing 7
NM_014570 26286 ARFGAP3 ADP-ribosylation factor GTPase activating protein 3
NM_002884 5906 RAP1A RAP1A, member of RAS oncogene family
NM_006936 6612 SUMO3 SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae)
NM_018247 55754 TMEM30A transmembrane protein 30A
NM_016041 51009 DERL2 Der1-like domain family, member 2
NM_005347 3309 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
NM_005719 10094 ARPC3 actin related protein 2/3 complex, subunit 3, 21kDa
NM_000395 1439 CSF2RB colony stimulating factor 2 receptor, beta, low-anity (granulocyte-
macrophage)
NM_002349 4065 LY75 lymphocyte antigen 75
NM_004125 NA NA NA
NM_005669 7905 REEP5 receptor accessory protein 5
NM_004580 5873 RAB27A RAB27A, member RAS oncogene family
NM_001779 965 CD58 CD58 molecule
NM_198892 55589 BMP2K BMP2 inducible kinase
NM_020375 57103 C12orf5 chromosome 12 open reading frame 5
NM_181777 7319 UBE2A ubiquitin-conjugating enzyme E2A (RAD6 homolog)
NM_004800 9375 TM9SF2 transmembrane 9 superfamily member 2
NM_006827 10972 TMED10 transmembrane emp24-like tracking protein 10 (yeast)
NM_016607 51566 ARMCX3 armadillo repeat containing, X-linked 3
NM_022168 64135 IFIH1 interferon induced with helicase C domain 1
NM_000201 3383 ICAM1 intercellular adhesion molecule 1
NM_004049 597 BCL2A1 BCL2-related protein A1
NM_005204 1326 MAP3K8 mitogen-activated protein kinase kinase kinase 8
NM_002053 2633 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa
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NM_004099 2040 STOM stomatin
NM_000434 4758 NEU1 sialidase 1 (lysosomal sialidase)
NM_002127 3135 HLA-G major histocompatibility complex, class I, G
NM_000593 6890 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
NM_002117 3107 HLA-C major histocompatibility complex, class I, C
X56841 3133 HLA-E major histocompatibility complex, class I, E
NM_005514 3106 HLA-B major histocompatibility complex, class I, B
NM_002116 3105 HLA-A major histocompatibility complex, class I, A
NM_004390 1512 CTSH cathepsin H
NM_004604 6810 STX4 syntaxin 4
NM_017631 55601 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
NM_004184 7453 WARS tryptophanyl-tRNA synthetase
NM_004172 6507 SLC1A3 solute carrier family 1 (glial high anity glutamate transporter),
member 3
NM_001995 2180 ACSL1 acyl-CoA synthetase long-chain family member 1
NM_014880 9936 CD302 CD302 molecule
NM_004938 1612 DAPK1 death-associated protein kinase 1
NM_203330 966 CD59 CD59 molecule, complement regulatory protein
NM_000712 644 BLVRA biliverdin reductase A
NM_006283 6867 TACC1 transforming, acidic coiled-coil containing protein 1
D29642 9938 ARHGAP25 Rho GTPase activating protein 25
NM_015033 23048 FNBP1 formin binding protein 1
NM_003768 8682 PEA15 phosphoprotein enriched in astrocytes 15
NM_003808 8741 TNFSF13 tumor necrosis factor (ligand) superfamily, member 13
NM_005561 3916 LAMP1 lysosomal-associated membrane protein 1
NM_002087 2896 GRN granulin
NM_003896 8869 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5
NM_019027 54502 RBM47 RNA binding motif protein 47
NM_014737 9770 RASSF2 Ras association (RalGDS/AF-6) domain family member 2
NM_002110 3055 HCK hemopoietic cell kinase
NM_030796 81552 VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1
NM_006399 10538 BATF basic leucine zipper transcription factor, ATF-like
NM_016545 51278 IER5 immediate early response 5
NM_199072 29969 MDFIC MyoD family inhibitor domain containing
NM_197966 637 BID BH3 interacting domain death agonist
NM_004710 9144 SYNGR2 synaptogyrin 2
NM_001621 196 AHR aryl hydrocarbon receptor
NM_001109 101 ADAM8 ADAM metallopeptidase domain 8
NM_021105 5359 PLSCR1 phospholipid scramblase 1
NM_030666 1992 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1
NM_052847 2788 GNG7 guanine nucleotide binding protein (G protein), gamma 7
NM_002827 5770 PTPN1 protein tyrosine phosphatase, non-receptor type 1
NM_001777 961 CD47 CD47 molecule
NM_005949 4494 MT1F metallothionein 1F
NM_004281 9531 BAG3 BCL2-associated athanogene 3
NM_000043 355 FAS Fas (TNF receptor superfamily, member 6)
NM_001421 2000 ELF4 E74-like factor 4 (ets domain transcription factor)
NM_017491 9948 WDR1 WD repeat domain 1
NM_006209 5168 ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2
NM_006403 4739 NEDD9 neural precursor cell expressed, developmentally down-regulated 9
NM_007315 6772 STAT1 signal transducer and activator of transcription 1, 91kDa
NM_018009 55080 TAPBPL TAP binding protein-like
NM_001084 8985 PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
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AF333388 645745 MT1P2 metallothionein 1 pseudogene 2
NM_144653 138151 NACC2 NACC family member 2, BEN and BTB (POZ) domain containing
NM_001719 655 BMP7 bone morphogenetic protein 7
NM_007289 4311 MME membrane metallo-endopeptidase
NM_000594 7124 TNF tumor necrosis factor
NM_005761 10154 PLXNC1 plexin C1
NM_006504 5791 PTPRE protein tyrosine phosphatase, receptor type, E
NM_172217 3603 IL16 interleukin 16 (lymphocyte chemoattractant factor)
NM_199040 11163 NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4
NM_005461 9935 MAFB v-maf musculoaponeurotic brosarcoma oncogene homolog B
(avian)
NM_012296 9846 GAB2 GRB2-associated binding protein 2
NM_030925 81617 CAB39L calcium binding protein 39-like
AF249277 400410 ST20 suppressor of tumorigenicity 20
NM_002118 3109 HLA-DMB major histocompatibility complex, class II, DM beta
NM_001276 1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)
NM_001334 1519 CTSO cathepsin O
NM_014153 29066 ZC3H7A zinc nger CCCH-type containing 7A
NM_006995 10385 BTN2A2 butyrophilin, subfamily 2, member A2
NM_018639 55884 WSB2 WD repeat and SOCS box-containing 2
NM_175617 4493 MT1E metallothionein 1E
NM_004688 9111 NMI N-myc (and STAT) interactor
NM_001066 7133 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B
NM_003978 9051 PSTPIP1 proline-serine-threonine phosphatase interacting protein 1
NM_003900 8878 SQSTM1 sequestosome 1
NM_002355 4074 M6PR mannose-6-phosphate receptor (cation dependent)
NM_003929 8934 RAB7L1 RAB7, member RAS oncogene family-like 1
NM_003299 7184 HSP90B1 heat shock protein 90kDa beta (Grp94), member 1
NM_015510 25979 DHRS7B dehydrogenase/reductase (SDR family) member 7B
NM_021194 7779 SLC30A1 solute carrier family 30 (zinc transporter), member 1
NM_000958 5734 PTGER4 prostaglandin E receptor 4 (subtype EP4)
NM_021136 6252 RTN1 reticulon 1
NM_007229 11252 PACSIN2 protein kinase C and casein kinase substrate in neurons 2
NM_001375 1777 DNASE2 deoxyribonuclease II, lysosomal
NM_000876 3482 IGF2R insulin-like growth factor 2 receptor
NM_022750 64761 PARP12 poly (ADP-ribose) polymerase family, member 12
NM_014435 27163 NAAA N-acylethanolamine acid amidase
NM_015194 4642 MYO1D myosin ID
NM_016602 2826 CCR10 chemokine (C-C motif) receptor 10
NM_002356 4082 MARCKS myristoylated alanine-rich protein kinase C substrate
NM_013313 29799 YPEL1 yippee-like 1 (Drosophila)
NM_001006109 56941 C3orf37 chromosome 3 open reading frame 37
NM_025079 80149 ZC3H12A zinc nger CCCH-type containing 12A
NM_006441 10588 MTHFS 5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate
cyclo-ligase)
NM_002231 3732 CD82 CD82 molecule
NM_020177 56929 FEM1C fem-1 homolog c (C. elegans)
NM_003454 7752 ZNF200 zinc nger protein 200
NM_002298 3936 LCP1 lymphocyte cytosolic protein 1 (L-plastin)
NM_002527 4908 NTF3 neurotrophin 3
NM_003219 7015 TERT telomerase reverse transcriptase
NM_019107 56005 C19orf10 chromosome 19 open reading frame 10
NM_212481 10865 ARID5A AT rich interactive domain 5A (MRF1-like)
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NM_017996 55070 DET1 de-etiolated homolog 1 (Arabidopsis)
NM_006277 50618 ITSN2 intersectin 2
NM_012198 25801 GCA grancalcin, EF-hand calcium binding protein
NM_032121 84061 MAGT1 magnesium transporter 1
NM_004090 1845 DUSP3 dual specicity phosphatase 3
NM_002068 2769 GNA15 guanine nucleotide binding protein (G protein), alpha 15 (Gq class)
NM_024324 79174 CRELD2 cysteine-rich with EGF-like domains 2
NM_002416 4283 CXCL9 chemokine (C-X-C motif) ligand 9
NM_006389 10525 HYOU1 hypoxia up-regulated 1
NM_017899 54997 TESC tescalcin
NM_001693 526 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2
NM_007161 7940 LST1 leukocyte specic transcript 1
NM_003190 6892 TAPBP TAP binding protein (tapasin)
NM_004059 883 CCBL1 cysteine conjugate-beta lyase, cytoplasmic
NM_016548 51280 GOLM1 golgi membrane protein 1
NM_012214 11320 MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A
NM_024310 79156 PLEKHF1 pleckstrin homology domain containing, family F (with FYVE do-
main) member 1
NM_147780 1508 CTSB cathepsin B
NM_002985 6352 CCL5 chemokine (C-C motif) ligand 5
NM_015441 25903 OLFML2B olfactomedin-like 2B
NM_014372 26994 RNF11 ring nger protein 11
NM_144977 163486 DENND1B DENN/MADD domain containing 1B
AB029551 23429 RYBP RING1 and YY1 binding protein
NM_002372 4124 MAN2A1 mannosidase, alpha, class 2A, member 1
NM_014923 22862 FNDC3A bronectin type III domain containing 3A
NM_005966 4664 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1)
NM_014624 6277 S100A6 S100 calcium binding protein A6
NM_005026 5293 PIK3CD phosphoinositide-3-kinase, catalytic, delta polypeptide
NM_001659 377 ARF3 ADP-ribosylation factor 3
NM_139265 30844 EHD4 EH-domain containing 4
NM_000521 3074 HEXB hexosaminidase B (beta polypeptide)
NM_006417 10561 IFI44 interferon-induced protein 44
NM_002528 4913 NTHL1 nth endonuclease III-like 1 (E. coli)
NM_001408 1952 CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 (amingo ho-
molog, Drosophila)
NM_022365 64215 DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1
NM_015567 26050 SLITRK5 SLIT and NTRK-like family, member 5
NM_006623 26227 PHGDH phosphoglycerate dehydrogenase
NM_016289 51719 CAB39 calcium binding protein 39
NM_006226 5334 PLCL1 phospholipase C-like 1
NM_014795 9839 ZEB2 zinc nger E-box binding homeobox 2
NM_003442 7702 ZNF143 zinc nger protein 143
NM_000487 410 ARSA arylsulfatase A
NM_013296 29899 GPSM2 G-protein signaling modulator 2
NM_001565 3627 CXCL10 chemokine (C-X-C motif) ligand 10
NM_006892 1789 DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta
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